0001564590-18-020497.txt : 20180808 0001564590-18-020497.hdr.sgml : 20180808 20180808162139 ACCESSION NUMBER: 0001564590-18-020497 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180808 DATE AS OF CHANGE: 20180808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL HEALTH REALTY INCOME TRUST CENTRAL INDEX KEY: 0000798783 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 236858580 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09321 FILM NUMBER: 181001659 BUSINESS ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH RD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: 610-265-0688 MAIL ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH ROAD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 10-Q 1 uht-10q_20180630.htm 10-Q uht-10q_20180630.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                      

Commission file number 1-9321

 

UNIVERSAL HEALTH REALTY INCOME TRUST

(Exact name of registrant as specified in its charter)

 

 

MARYLAND

 

23-6858580

(State or other jurisdiction of

incorporation or organization)

 

(I. R. S. Employer

Identification No.)

 

 

 

UNIVERSAL CORPORATE CENTER

367 SOUTH GULPH ROAD

KING OF PRUSSIA, PENNSYLVANIA

 

19406

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code (610) 265-0688

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated Filer

 

 

 

 

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Number of common shares of beneficial interest outstanding at July 31, 2018—13,745,138

 

 

 

 

 


HEALTH REALTY INCOME TRUST

INDEX

 

 

 

 

 

PAGE NO.

PART I. FINANCIAL INFORMATION (unaudited)

 

 

Item 1.

 

Financial Statements

 

 

 

 

Condensed Consolidated Statements of Income—Three and Six Months Ended June 30, 2018 and 2017

 

3

 

 

Condensed Consolidated Statements of Comprehensive Income—Three and Six Months Ended June 30, 2018 and 2017

 

4

 

 

Condensed Consolidated Balance Sheets—June 30, 2018 and December 31, 2017

 

5

 

 

Condensed Consolidated Statements of Cash Flows—Six Months Ended June 30, 2018 and 2017

 

6

 

 

Notes to Condensed Consolidated Financial Statements

 

7 through 15

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

16 through 26

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

26

Item 4.

 

Controls and Procedures

 

27

PART II. OTHER INFORMATION

 

28

Item 6.

 

Exhibits

 

28

EXHIBIT INDEX

 

29

 

 

 

 

 

Signatures

 

30

 

 

 

This Quarterly Report on Form 10-Q is for the quarter ended June 30, 2018. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

As disclosed in this Quarterly Report, including in Note 2 to the Condensed Consolidated Financial Statements—Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions, a wholly-owned subsidiary of UHS (UHS of Delaware, Inc.) serves as our Advisor pursuant to the terms of an annually renewable Advisory Agreement dated December 24, 1986. Our officers are all employees of UHS through its wholly-owned subsidiary, UHS of Delaware, Inc. In addition, three of our hospital facilities are leased to subsidiaries of UHS, and subsidiaries of UHS are tenants of seventeen medical office buildings or free-standing emergency departments, that are either wholly or jointly-owned by us. Any reference to “UHS” or “UHS facilities” in this report is referring to Universal Health Services, Inc.’s subsidiaries, including UHS of Delaware, Inc.

In this Quarterly Report, the term “revenues” does not include the revenues of the four unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%. We currently account for our share of the income/loss from these investments by the equity method (see Note 5 to the Condensed Consolidated Financial Statements included herein).

 

 

 

 


 

Part I. Financial Information

Item I. Financial Statements

Universal Health Realty Income Trust

Condensed Consolidated Statements of Income

For the Three and Six Months Ended June 30, 2018 and 2017

(amounts in thousands, except per share amounts)

(unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Base rental - UHS facilities

 

$

4,187

 

 

$

4,303

 

 

$

8,363

 

 

$

8,383

 

Base rental - Non-related parties

 

 

10,217

 

 

 

10,116

 

 

 

20,544

 

 

 

20,086

 

Bonus rental - UHS facilities

 

 

1,204

 

 

 

1,242

 

 

 

2,530

 

 

 

2,530

 

Tenant reimbursements and other - Non-related parties

 

 

4,200

 

 

 

2,239

 

 

 

6,615

 

 

 

4,432

 

Tenant reimbursements and other - UHS facilities

 

 

303

 

 

 

245

 

 

 

598

 

 

 

464

 

 

 

 

20,111

 

 

 

18,145

 

 

 

38,650

 

 

 

35,895

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

6,111

 

 

 

6,295

 

 

 

12,398

 

 

 

12,440

 

Advisory fees to UHS

 

 

948

 

 

 

874

 

 

 

1,852

 

 

 

1,740

 

Other operating expenses

 

 

5,445

 

 

 

4,923

 

 

 

10,653

 

 

 

9,628

 

Transaction costs

 

 

-

 

 

 

56

 

 

 

-

 

 

 

126

 

 

 

 

12,504

 

 

 

12,148

 

 

 

24,903

 

 

 

23,934

 

Income before equity in income of unconsolidated limited liability companies ("LLCs"), interest expense, hurricane insurance recovery proceeds and gain

 

 

7,607

 

 

 

5,997

 

 

 

13,747

 

 

 

11,961

 

Equity in income of unconsolidated LLCs

 

 

425

 

 

 

498

 

 

 

854

 

 

 

1,575

 

     Hurricane insurance recovery proceeds in excess of damaged property

     write-downs

 

 

-

 

 

 

-

 

 

 

4,535

 

 

 

-

 

     Hurricane business interruption insurance recovery proceeds

 

 

194

 

 

 

-

 

 

 

1,162

 

 

 

-

 

Gain on Arlington transaction

 

 

-

 

 

 

-

 

 

 

-

 

 

 

27,196

 

Interest expense, net

 

 

(2,421

)

 

 

(2,462

)

 

 

(4,889

)

 

 

(5,137

)

Net income

 

$

5,805

 

 

$

4,033

 

 

$

15,409

 

 

$

35,595

 

Basic earnings per share

 

$

0.42

 

 

$

0.30

 

 

$

1.12

 

 

$

2.62

 

Diluted earnings per share

 

$

0.42

 

 

$

0.30

 

 

$

1.12

 

 

$

2.62

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding - Basic and Diluted

 

 

13,720

 

 

 

13,583

 

 

 

13,719

 

 

 

13,581

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

3


 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Comprehensive Income

For the Three and Six Months Ended June 30, 2018 and 2017

(dollar amounts in thousands)

(unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Net income

 

$

5,805

 

 

$

4,033

 

 

$

15,409

 

 

$

35,595

 

Other comprehensive income/(loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized derivative gain/(loss) on interest rate caps

 

 

6

 

 

 

(75

)

 

 

154

 

 

 

(93

)

Total other comprehensive income/(loss):

 

 

6

 

 

 

(75

)

 

 

154

 

 

 

(93

)

Total comprehensive income

 

$

5,811

 

 

$

3,958

 

 

$

15,563

 

 

$

35,502

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

4


 

Universal Health Realty Income Trust

Condensed Consolidated Balance Sheets

(dollar amounts in thousands)

(unaudited)

 

 

 

June 30,

 

 

December 31,

 

 

 

2018

 

 

2017

 

Assets:

 

 

 

 

 

 

 

 

Real Estate Investments:

 

 

 

 

 

 

 

 

Buildings and improvements and construction in progress

 

$

553,970

 

 

$

546,634

 

Accumulated depreciation

 

 

(163,434

)

 

 

(153,379

)

 

 

 

390,536

 

 

 

393,255

 

Land

 

 

53,396

 

 

 

53,142

 

               Net Real Estate Investments

 

 

443,932

 

 

 

446,397

 

Investments in limited liability companies ("LLCs")

 

 

4,655

 

 

 

4,671

 

Other Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

5,732

 

 

 

3,387

 

Base and bonus rent and other receivables from UHS

 

 

2,610

 

 

 

2,680

 

Rent receivable - other

 

 

6,829

 

 

 

6,422

 

Intangible assets (net of accumulated amortization of $25.7 million and

   $28.7 million at June 30, 2018 and December 31, 2017, respectively)

 

 

19,253

 

 

 

20,559

 

Deferred charges and other assets, net

 

 

7,991

 

 

 

5,892

 

               Total Assets

 

$

491,002

 

 

$

490,008

 

Liabilities:

 

 

 

 

 

 

 

 

Line of credit borrowings

 

$

197,250

 

 

$

181,050

 

Mortgage notes payable, non-recourse to us, net

 

 

52,806

 

 

 

75,359

 

Accrued interest

 

 

504

 

 

 

540

 

Accrued expenses and other liabilities

 

 

12,193

 

 

 

12,188

 

Dividends payable

 

 

9,156

 

 

 

-

 

Tenant reserves, deposits and deferred and prepaid rents

 

 

11,103

 

 

 

10,310

 

               Total Liabilities

 

 

283,012

 

 

 

279,447

 

Equity:

 

 

 

 

 

 

 

 

Preferred shares of beneficial interest,

   $.01 par value; 5,000,000 shares authorized;

   none issued and outstanding

 

 

-

 

 

 

-

 

Common shares, $.01 par value;

   95,000,000 shares authorized; issued and outstanding: 2018 - 13,744,229;

   2017 - 13,735,369

 

 

137

 

 

 

137

 

Capital in excess of par value

 

 

265,544

 

 

 

265,335

 

Cumulative net income

 

 

633,529

 

 

 

618,120

 

Cumulative dividends

 

 

(691,518

)

 

 

(673,175

)

Accumulated other comprehensive income

 

 

298

 

 

 

144

 

     Total Equity

 

 

207,990

 

 

 

210,561

 

               Total Liabilities and Equity

 

$

491,002

 

 

$

490,008

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

5


 

Universal Health Realty Income Trust

Condensed Consolidated Statement of Cash Flows

(dollar amounts in thousands)

(unaudited)

 

 

 

Six months ended June 30,

 

 

 

2018

 

 

2017

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income

 

$

15,409

 

 

$

35,595

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

12,288

 

 

 

12,476

 

Amortization of debt premium

 

 

(23

)

 

 

(100

)

Stock-based compensation expense

 

 

254

 

 

 

252

 

Hurricane insurance recovery proceeds in excess of damaged property write-downs

 

 

(4,535

)

 

 

 

Gain on Arlington transaction

 

 

 

 

 

(27,196

)

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Rent receivable

 

 

(337

)

 

 

(683

)

Accrued expenses and other liabilities

 

 

(445

)

 

 

(398

)

Tenant reserves, deposits and deferred and prepaid rents

 

 

713

 

 

 

79

 

Accrued interest

 

 

(36

)

 

 

(62

)

Leasing costs paid

 

 

(597

)

 

 

(403

)

Other, net

 

 

517

 

 

 

783

 

Net cash provided by operating activities

 

 

23,208

 

 

 

20,343

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Investments in LLCs

 

 

(369

)

 

 

(532

)

Repayments of advances made to LLC

 

 

 

 

 

216

 

Cash distributions in excess of income from LLCs

 

 

501

 

 

 

734

 

Additions to real estate investments, net

 

 

(4,246

)

 

 

(6,537

)

Cash proceeds received from divestiture of property, net of restricted cash

 

 

 

 

 

53,967

 

Restricted cash proceeds from divestiture of property

 

 

 

 

 

11,253

 

Hurricane insurance recovery proceeds in excess of damaged property write-downs

 

 

4,535

 

 

 

 

Hurricane remediation payments

 

 

(192

)

 

 

 

Deposits on real estate

 

 

 

 

 

(150

)

Net cash paid for acquisition of property

 

 

(4,053

)

 

 

 

Cash paid to acquire minority interests in majority-owned LLCs

 

 

 

 

 

(7,890

)

Net cash (used in)/provided by investing activities

 

 

(3,824

)

 

 

51,061

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Net borrowings/(repayments) on line of credit

 

 

16,200

 

 

 

(18,650

)

Repayments of mortgage notes payable

 

 

(22,585

)

 

 

(36,473

)

Proceeds from mortgage notes payable

 

 

 

 

 

13,200

 

Financing costs paid

 

 

(1,527

)

 

 

(284

)

Dividends paid

 

 

(9,187

)

 

 

(17,887

)

Issuance of shares of beneficial interest, net

 

 

60

 

 

 

122

 

Net cash used in financing activities

 

 

(17,039

)

 

 

(59,972

)

Increase in cash, cash equivalents and restricted cash

 

 

2,345

 

 

 

11,432

 

Cash, cash equivalents and restricted cash, beginning of period

 

 

3,387

 

 

 

3,930

 

Cash, cash equivalents and restricted cash, end of period

 

$

5,732

 

 

$

15,362

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

 

Interest paid

 

$

4,711

 

 

$

5,039

 

 

See accompanying notes to these condensed consolidated financial statements.

 

6


 

UNIVERSAL HEALTH REALTY INCOME TRUST

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2018

(unaudited)

 

(1) General

This Quarterly Report on Form 10-Q is for the quarter ended June 30, 2018. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.  As of June 30, 2018, we had investments in four jointly-owned LLCs/LPs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.

The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2017.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Certain prior period amounts on our statement of cash flows have been reclassified to conform to the current period presentation in connection with our adoption of ASU No. 2016-18, Restricted Cash.

 

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each of the three hospital facilities leased to subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 20% and 22% of our consolidated revenues for the three months ended June 30, 2018 and 2017, respectively, and approximately 21% and 23% of our consolidated revenues for the six months ended June 30, 2018 and 2017, respectively. In addition, we have seventeen medical office buildings (“MOBs”), or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us, that include tenants which are subsidiaries of UHS.  The aggregate revenues generated from UHS-related tenants comprised approximately 28% and 32% of our consolidated revenues during the three-month periods ended June 30, 2018 and 2017, respectively, and approximately 30% and 32% of our consolidated revenues during the six-month periods ended June 30, 2018 and 2017, respectively.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month’s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.

In June, 2018, McAllen Medical Center, a wholly-owned subsidiary of UHS, provided notice to us, exercising the 5-year renewal option on their lease.  The renewal extended the lease term on this facility, at the existing lease rate, to December, 2026.

7


 

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2026

 

 

5

 

(a)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(b)

 

(a)

UHS has one 5-year renewal option at the existing lease rate (through 2031).

(b)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.  

In April, 2017, the recently constructed Henderson Medical Plaza MOB received its certificate of occupancy. Henderson Medical Plaza is located on the campus of the Henderson Hospital Medical Center, a newly constructed acute care hospital that is owned and operated by a subsidiary of UHS and was completed and opened during the fourth quarter of 2016.  A ground lease has been executed between the limited liability company that owns the MOB and a subsidiary of UHS, the terms of which include a seventy-five year lease term with two, ten-year renewal options at the lessee’s option at an adjusting lease rate. We have invested net cash of approximately $13.0 million on the development and construction of this MOB as of June 30, 2018.

Advisory Agreement:    UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the “Advisory Agreement”) dated December 24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. Our advisory fee is 0.70% of our average invested real estate assets, as derived from our consolidated balance sheet. In December of 2017, based upon a review of our advisory fee and other general and administrative expenses as compared to an industry peer group, the Advisory Agreement was renewed for 2018 pursuant to the same terms as the Advisory Agreement in place since 2013.

The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid at any time since our inception since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $948,000 and $874,000 for the three months ended June 30, 2018 and 2017, respectively, and were based upon average invested real estate assets of $542 million and $499 million for the three-month periods ended June 30, 2018 and 2017, respectively.  Advisory fees incurred and paid (or payable) to UHS amounted to $1.9 million and $1.7 million for the six months ended June 30, 2018 and 2017, respectively, and were based upon average invested real estate assets of $529 million and $497 million for the six-month periods ended June 30, 2018 and 2017, respectively

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of June 30, 2018 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock.

8


 

In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

Share Ownership: At each of June 30, 2018 and December 31, 2017, UHS owned 5.7%, of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 28% and 32% of our consolidated revenues during the three-month periods ended June 30, 2018 and 2017, respectively, and 30% and 32% of our consolidated revenues during the six-month periods ended June 30, 2018 and 2017, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

(3) Dividends

Dividends:

We declared dividends of $9.2 million, or $.67 per share, during the second quarter of 2018, which were paid on July 3, 2018.  We declared and paid dividends of $9.0 million, or $.66 per share, during the second quarter of 2017. During the six-month period ended June 30, 2018, we declared dividends of $18.3 million, or $1.335 per share, $9.2 million of which was paid on July 3, 2018. We declared and paid dividends of $17.9 million, or $1.315 per share, during the six-month period ended June 30, 2017.

(4) Acquisitions and Dispositions

Six Months Ended June 30, 2018:

Acquisitions:

In June, 2018, we acquired the Beaumont Medical Sleep Center Building located in Southfield, Michigan for a purchase price of approximately $4.0 million.  This building is 100% leased under the terms of a triple net lease with a remaining initial lease term of approximately 9.5 years at the time of purchase, with two, five year renewal options.

Dispositions:

There were no dispositions during the first six months of 2018.

Six Months Ended June 30, 2017:

Acquisitions:

 There were no acquisitions during the first six months of 2017.

Disposition:

During March, 2017, Arlington Medical Properties, LLC, a formerly jointly-owned limited liability company in which we held an 85% noncontrolling ownership interest, sold the real estate assets of St. Mary’s Professional Office Building (“St. Mary’s”) as part of a series of planned tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.  St. Mary’s is a multi-tenant medical office building located in Reno, Nevada.  A third party member owned the remaining 15% of Arlington Medical Properties LLC, which we acquired prior to the divestiture of St. Mary’s for a purchase price of $7.9 million. The divestiture of St. Mary’s generated an aggregate of approximately $57.3 million of net cash proceeds to us (approximately $11.3 million of which was held as restricted cash by a qualified 1031 exchange intermediary until the third quarter of 2017).  These proceeds, which were net of closing costs and the purchase price paid for the minority member’s ownership interest in the LLC, include repayment to us of a $21.4 million member loan.  Our results of operations for the six-month period ended June 30, 2017 included a net gain of $27.2 million (net of related transaction costs) recorded in connection with this transaction.

(5) Summarized Financial Information of Equity Affiliates

In accordance with the Financial Accounting Standards Board’s (“FASB”) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds

9


 

and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

In the Condensed Consolidated Statements of Cash Flows, distributions and equity in net income are presented net as cash flows from operating activities. Cumulative distributions received exceeding cumulative equity in earnings represent returns of investments and are classified as cash flows from investing activities in the Condensed Consolidated Statements of Cash Flows.

At June 30, 2018, we have non-controlling equity investments or commitments in four jointly-owned LLCs/LPs which own MOBs. As of June 30, 2018, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties.

 The following property table represents the four LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of June 30, 2018:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

 

(a.)

This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of June 30, 2018.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of June 30, 2018.

(c.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of June 30, 2018.  This LP has a third-party term loan, which is non-recourse to us, of $5.1 million outstanding as of June 30, 2018.

Below are the condensed combined statements of income (unaudited) for the LLCs/LPs accounted for under the equity method during the three and six months ended June 30, 2018 and 2017.  The six months ended June 30, 2017 include the financial results of Arlington Medical Properties, LLC, through the March 13, 2017 divestiture date.  

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

 

 

 

(amounts in thousands)

(amounts in thousands)

Revenues

 

$

2,451

 

 

$

2,410

 

 

$

4,913

 

 

$

5,993

 

 

Operating expenses

 

 

977

 

 

 

939

 

 

 

1,935

 

 

 

2,189

 

 

Depreciation and amortization

 

 

438

 

 

 

421

 

 

 

895

 

 

 

1,064

 

 

Interest, net

 

 

328

 

 

 

337

 

 

 

656

 

 

 

899

 

 

Net income

 

$

708

 

 

$

713

 

 

$

1,427

 

 

$

1,841

 

 

Our share of net income (a.)

 

$

425

 

 

$

498

 

 

$

854

 

 

$

1,575

 

 

 

(a.)

Our share of net income for the six months ended June 30, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC.  This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.  

 

10


 

Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs that were accounted for under the equity method as of June 30, 2018 and December 31, 2017:

 

 

 

June 30,

2018

 

 

December 31,

2017

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

32,345

 

 

$

33,111

 

Other assets

 

 

3,659

 

 

 

3,560

 

Total assets

 

$

36,004

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Other liabilities

 

$

2,654

 

 

$

3,067

 

Mortgage notes payable, non-recourse to us

 

 

27,548

 

 

 

27,839

 

Equity

 

 

5,802

 

 

 

5,765

 

Total liabilities and equity

 

$

36,004

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Investments in LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

4,655

 

 

$

4,671

 

   Amounts included in accrued expenses and other liabilities

 

 

(2,011

)

 

 

(1,895

)

Our share of equity in LLCs, net

 

$

2,644

 

 

$

2,776

 

   

As of June 30, 2018, and December 31, 2017, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

6/30/2018

 

 

12/31/2017

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan)

 

$

5,134

 

 

$

5,202

 

 

October, 2020

Grayson Properties (5.034% fixed rate mortgage loan)

 

 

14,060

 

 

 

14,191

 

 

September, 2021

Brunswick Associates (3.64% fixed rate mortgage loan)

 

 

8,354

 

 

 

8,446

 

 

December, 2024

 

 

$

27,548

 

 

$

27,839

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

Pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

(6) Recent Accounting Pronouncements

On January 1, 2018, we adopted ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows, and ASU 2016-18, Restricted Cash, which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows.  We adopted these ASUs by applying a retrospective transition method which requires a reclassification of our Consolidated Statement of Cash Flows for the period ending June 30, 2017. The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:

 

 

 

 

(In thousands)

 

June 30, 2018

 

 

June 30, 2017

 

Cash and cash equivalents

 

$

5,732

 

 

$

4,109

 

Restricted cash

 

 

-

 

 

 

11,253

 

Total Cash, Cash Equivalents and Restricted Cash

 

$

5,732

 

 

$

15,362

 

 

11


 

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which introduces a lessee model that brings most leases on the balance sheet and, among other changes, eliminates the requirement in current Generally Accepted Accounting Principles in the United States of America “GAAP”) for an entity to use bright-line tests in determining lease classification. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements.

 

On January 1, 2018, we adopted ASU 2014-09, Revenue From Contracts With Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted the standard on January 1, 2018, using the modified retrospective approach, which requires a cumulative-effect adjustment to equity as of the date of adoption.   ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment.  The adoption of this standard did not have a significant impact on our consolidated financial statements and no cumulative adjustment was recorded upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.

 

Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals) and bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.  We apply FASB ASC Topic 606, “Revenue from Contracts with Customers” with respect to tenant reimbursement and other property income, which totaled $2.8 million and $2.5 million for the three months ended June 30, 2018 and 2017, respectively, and $5.5 million and $4.9 million for the six months ended June 30, 2018 and 2017, respectively.  The 2018 three and six month tenant reimbursement and other property income amounts also include a $1.7 million early lease termination fee recorded during the three months ended June 30, 2018. Tenant reimbursements for operating expenses are accrued as revenue and generally due monthly from tenants.  Since payments with respect to tenant reimbursement income are generally due monthly, no contract assets or liabilities have been recognized.  Revenue consisting of rental income from leasing arrangements are specifically excluded from FASB ASC Topic 606.

(7) Debt and Financial Instruments

Debt:

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $300 million revolving credit agreement, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On March 27, 2018, we entered into a revolving credit agreement (“Credit Agreement”) which, among other things, increased our borrowing capacity by $50 million to $300 million and extended the maturity date from our previously existing facility. The replacement Credit Agreement, which is scheduled to mature in March, 2022, includes a $40 million sublimit for letters of credit and a $30 million sub limit for swingline/short-term loans.  The Credit Agreement also provides for options to extend the maturity date for two additional six month periods. Additionally, the Credit Agreement includes an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement.  Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines “Base Rate” as the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At June 30, 2018, the applicable margin over the LIBOR rate was 1.15%, the margin over the Base Rate was 0.15%, and the facility fee was 0.20%.  

12


 

At June 30, 2018, we had $197.3 million of outstanding borrowings under our Credit Agreement and $102.7 million of available borrowing capacity.  There are no compensating balance requirements.  As disclosed below, during the first six months of 2018, we repaid an aggregate of $21.7 million on three mortgages utilizing borrowings under our Credit Agreement.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at June 30, 2018. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

June 30,

2018

 

Tangible net worth

 

> =$125,000

 

$

188,737

 

Total leverage

 

< 60%

 

 

39.9

%

Secured leverage

 

< 30%

 

 

8.1

%

Unencumbered leverage

 

< 60%

 

 

36.2

%

Fixed charge coverage

 

> 1.50x

 

4.1x

 

 

As indicated on the following table, we have eight mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of June 30, 2018 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

$

2,573

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

5,961

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,028

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,877

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,940

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

13,198

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

4,273

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

9,307

 

 

 

3.95

%

 

January, 2030

Total, excluding net debt premium and net financing fees

 

 

53,157

 

 

 

 

 

 

 

     Less net financing fees

 

 

(625

)

 

 

 

 

 

 

     Plus net debt premium

 

 

274

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

52,806

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

 

On February 13, 2018, upon its maturity, a $4.1 million floating rate mortgage loan on the Sparks Medical Building/Vista Medical Terrace was fully repaid utilizing borrowings under our Credit Agreement.  

13


 

On April 5, 2018, upon its maturity, a $9.7 million floating rate mortgage loan on the Centennial Hills Medical Office Building was fully repaid utilizing borrowings under our Credit Agreement.

On May 2, 2018, upon its maturity, a $7.9 million fixed rate mortgage loan on the Rosenberg Children’s Medical Plaza was fully repaid utilizing borrowings under our Credit Agreement.  

The mortgages are secured by the real property of the buildings as well as property leases and rents. The eight mortgages outstanding as of June 30, 2018 had a combined fair value of approximately $53.0 million. The fair value of our debt was computed based upon quotes received from financial institutions.  We consider these to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments.  Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

At December 31, 2017, we had eleven mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these eleven mortgages was $75.7 million and had a combined fair value of approximately $76.3 million.

Financial Instruments:

During the second quarter of 2016, we entered into an interest rate cap on the total notional amount of $30 million whereby we paid a premium of $115,000.  In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap.  This interest rate cap became effective in January, 2017 and expires in March, 2019. From inception through June 30, 2018, we received or accrued approximately $39,000 in payments made to us by the counterparties (all received during the first six months of 2018) pursuant to the terms of these caps.

During the third quarter of 2016, we entered into an additional interest rate cap agreement on a total notional amount of $30 million whereby we paid a premium of $55,000.  In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.5% and one-month LIBOR if one-month LIBOR rises above 1.5% during the term of the cap.  This interest rate cap became effective in October, 2016 and expires in March, 2019.  From inception through June 30, 2018, we received or accrued approximately $39,000 in payments made to us by the counterparties (all received during the first six months of 2018) pursuant to the terms of these caps.

(8) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  No individual property meets the requirements necessary to be considered its own segment.

(9) Impact of Hurricane Harvey  

In late August, 2017, five of our medical office buildings listed below located in the Houston, Texas area incurred extensive water damage as a result of Hurricane Harvey. Until various times during the second quarter of 2018, these properties were temporarily closed and non-operational as we continued to reconstruct and restore them to operational condition. As of June 30, 2018, reconstruction on all of the occupied space in these properties has been completed and operations have resumed.

 

During 2018, pursuant to the terms of a global settlement with our commercial property insurance carrier, we received $5.5 million of additional insurance recovery proceeds bringing the aggregate hurricane-related insurance recoveries to $12.5 million.  The aggregate insurance proceeds recoveries, which are net of applicable deductibles, covered substantially all of the costs incurred related to the remediation, repair and reconstruction of each of these properties as well as business interruption recoveries for the lost income related to each of these properties during the period they were non-operational.

 

14


 

Our financial results for the three months ended June 30, 2018 include approximately $194,000 of business interruption insurance recovery proceeds. Our financial results for the six months ended June 30, 2018 include approximately $1.2 million of business interruption insurance recovery proceeds, covering the period of late August, 2017 through June 30, 2018, approximately $500,000 of which relates to 2017. These business interruption insurance recovery proceeds are included in net cash provided by operating activities in our condensed consolidated statement of cash flows for the six-month period ended June 30, 2018. Additionally, the six months ended June 30, 2018 includes approximately $4.5 million of hurricane insurance recoveries in excess of property damage write-downs, which are included in net cash provided by investing activities in our condensed consolidated statement of cash flows for the six-month period ended June 30, 2018.

 

Our properties damaged and temporarily closed from Hurricane Harvey were:

 

Cypresswood Professional Center – located in Spring, Texas and consisting of two MOBs.

 

Professional Buildings at King’s Crossing – located in Kingwood, Texas and consisting of two MOBs.

 

Kelsey-Seybold Clinic at King’s Crossing – located in Kingwood, Texas and consisting of one MOB.

15


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a real estate investment trust (“REIT”) that commenced operations in 1986. We invest in healthcare and human service related facilities currently including acute care hospitals, rehabilitation hospitals, sub-acute facilities, surgery centers, free-standing emergency departments, childcare centers and medical/office buildings. As of July 31, 2018, we have sixty-nine real estate investments located in twenty states consisting of:

 

six hospital facilities consisting of three acute care, one rehabilitation and two sub-acute;

 

fifty-five medical/office buildings, including four owned by unconsolidated limited liability companies (“LLCs”)/limited liability partnerships (“LPs”);

 

four free-standing emergency departments (“FEDs”), and;

 

four pre-school and childcare centers.

Forward Looking Statements and Certain Risk Factors

You should carefully review all of the information contained in this Quarterly Report, and should particularly consider any risk factors that we set forth in this Quarterly Report and in other reports or documents that we file from time to time with the Securities and Exchange Commission (the “SEC”). In this Quarterly Report, we state our beliefs of future events and of our future financial performance. In some cases, you can identify those so-called “forward-looking statements” by words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “appears,” “projects” and similar expressions, as well as statements in future tense. You should be aware that those statements are only our predictions. Actual events or results may differ materially. In evaluating those statements, you should specifically consider various factors, including the risks outlined herein and in our Annual Report on Form 10-K for the year ended December 31, 2017 in Item 1A Risk Factors and in Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations—Forward Looking Statements. Those factors may cause our actual results to differ materially from any of our forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, such performance or results will be achieved. Forward-looking information is based on information available at the time and/or our good faith belief with respect to future events, and is subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Such factors include, among other things, the following:  

 

a substantial portion of our revenues are dependent upon one operator, Universal Health Services, Inc. (“UHS”). We cannot assure you that subsidiaries of UHS will renew the leases on our three acute care hospitals (two of which are scheduled to expire in December, 2021 and one of which is scheduled to expire in December, 2026) and two FEDs at existing lease rates or fair market value lease rates. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital facilities and FEDs upon expiration of the lease terms, our future revenues and results of operations could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to these leases;

 

in certain of our markets, the general real estate market has been unfavorably impacted by increased competition/capacity and decreases in occupancy and rental rates which may adversely impact our operating results and the underlying value of our properties;

 

a number of legislative initiatives have recently been passed into law that may result in major changes in the health care delivery system on a national or state level to the operators of our facilities, including UHS. No assurances can be given that the implementation of these new laws will not have a material adverse effect on the business, financial condition or results of operations of our operators;

 

the potential indirect impact of the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”), signed into law on December 22, 2017, which makes significant changes to corporate and individual tax rates and calculation of taxes, which could potentially impact our tenants and jurisdictions, both positively and negatively, in which we do business, as well as the overall investment thesis for REITs;

 

a subsidiary of UHS is our Advisor and our officers are all employees of a wholly-owned subsidiary of UHS, which may create the potential for conflicts of interest;

 

lost revenues resulting from the exercise of purchase options, lease expirations and renewals and other restructuring;

16


 

 

our ability to continue to obtain capital on acceptable terms, including borrowed funds, to fund future growth of our business;

 

the outcome and effects of known and unknown litigation, government investigations, and liabilities and other claims asserted against us, UHS or the other operators of our facilities. UHS and its subsidiaries are subject to pending legal actions, purported shareholder class actions and shareholder derivative cases, governmental investigations and regulatory actions and the effects of adverse publicity relating to such matters. Since UHS comprised approximately 30% of our consolidated revenues during the six-month period ended June 30, 2018, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain and review the disclosures contained in the Legal Proceedings section of Universal Health Services, Inc.’s Forms 10-Q and 10-K, as publicly filed with the Securities and Exchange Commission. Those filings are the sole responsibility of UHS and are not incorporated by reference herein;

 

failure of UHS or the other operators of our hospital facilities to comply with governmental regulations related to the Medicare and Medicaid licensing and certification requirements could have a material adverse impact on our future revenues and the underlying value of the property;

 

the potential unfavorable impact on our business of deterioration in national, regional and local economic and business conditions, including a worsening of credit and/or capital market conditions, which may adversely affect our ability to obtain capital which may be required to fund the future growth of our business and refinance existing debt with near term maturities;

 

a deterioration in general economic conditions which could result in increases in the number of people unemployed and/or insured and likely increase the number of individuals without health insurance; as a result, the operators of our facilities may experience decreases in patient volumes which could result in decreased occupancy rates at our medical office buildings;

 

a worsening of the economic and employment conditions in the United States could materially affect the business of our operators, including UHS, which may unfavorably impact our future bonus rentals (on the UHS hospital facilities) and may potentially have a negative impact on the future lease renewal terms and the underlying value of the hospital properties;

 

real estate market factors, including without limitation, the supply and demand of office space and market rental rates, changes in interest rates as well as an increase in the development of medical office condominiums in certain markets;

 

the impact of property values and results of operations of severe weather conditions, including the effects of Hurricane Harvey on several of our properties in Texas;

 

government regulations, including changes in the reimbursement levels under the Medicare and Medicaid programs;

 

the issues facing the health care industry that affect the operators of our facilities, including UHS, such as: changes in, or the ability to comply with, existing laws and government regulations; unfavorable changes in the levels and terms of reimbursement by third party payors or government programs, including Medicare (including, but not limited to, the potential unfavorable impact of future reductions to Medicare reimbursements resulting from the Budget Control Act of 2011, as discussed below) and Medicaid (most states have reported significant budget deficits that have, in the past, resulted in the reduction of Medicaid funding to the operators of our facilities, including UHS); demographic changes; the ability to enter into managed care provider agreements on acceptable terms; an increase in uninsured and self-pay patients which unfavorably impacts the collectability of patient accounts; decreasing in-patient admission trends; technological and pharmaceutical improvements that may increase the cost of providing, or reduce the demand for, health care, and; the ability to attract and retain qualified medical personnel, including physicians;

 

in August, 2011, the Budget Control Act of 2011 (the “2011 Act”) was enacted into law. The 2011 Act imposed annual spending limits for most federal agencies and programs aimed at reducing budget deficits by $917 billion between 2012 and 2021, according to a report released by the Congressional Budget Office. The 2011 Act provides for new spending on program integrity initiatives intended to reduce fraud and abuse under the Medicare program. Among its other provisions, the law established a bipartisan Congressional committee, known as the Joint Select Committee on Deficit Reduction (the “Joint Committee”), which was tasked with making recommendations aimed at reducing future federal budget deficits by an additional $1.5 trillion over 10 years. The Joint Committee was unable to reach an agreement by the November 23, 2011 deadline and, as a result, across-the-board cuts to discretionary, national defense and Medicare spending were implemented on March 1, 2013 resulting in Medicare payment reductions of up to 2% per fiscal year with a uniform percentage reduction across all Medicare programs. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, continued the 2% reductions to Medicare reimbursement imposed under the 2011 Act.  We cannot predict whether Congress will restructure the implemented Medicare payment reductions or what federal other deficit reduction initiatives

17


 

 

may be proposed by Congress going forward. We also cannot predict the effect these enactments will have on operators (including UHS), and, thus, our business;

 

in March, 2010, the Health Care and Education Reconciliation Act of 2010 and the Patient Protection and Affordable Care Act (the “ACA”) were enacted into law and created significant changes to health insurance coverage for U.S. citizens as well as material revisions to the federal Medicare and state Medicaid programs. The two combined primary goals of these acts are to provide for increased access to coverage for healthcare and to reduce healthcare-related expenses. Medicare, Medicaid and other health care industry changes are scheduled to be implemented at various times during this decade.  Initiatives to repeal the ACA, in whole or in part, to delay elements of implementation or funding, and to offer amendments or supplements to modify its provisions, have been persistent. The ultimate outcomes of legislative attempts to repeal or amend the ACA and legal challenges to the ACA are unknown.  Recent Congressional and Presidential election results created a political environment in which there have been repeated attempts to repeal or replace substantial portions of the ACA; 

 

Legislation has already been enacted that has repealed the individual mandate to obtain health insurance penalty that had been required by the ACA.  In addition, Congress is considering legislation that would, in material part: (i) eliminate the large employer mandates to provide health insurance coverage; (ii) permit insurers to impose a surcharge up to 30 percent on individuals who go uninsured for more than two months and then purchase coverage; (iii) provide tax credits towards the purchase of health insurance, with a phase-out of tax credits accordingly to income level; (iv) expand health savings accounts; (v) impose a per capita cap on federal funding of state Medicaid programs, or, if elected by a state, transition federal funding to block grants, and; (vi) permit states to seek a waiver of certain federal requirements that would allow such state to define essential health benefits differently from federal standards and that would allow certain commercial health plans to take health status, including pre-existing conditions, into account in setting premiums.   In addition to legislative changes, the Legislation can be significantly impacted by executive branch actions. In relevant part, President Trump has already taken executive actions: (i) requiring all federal agencies with authorities and responsibilities under the Legislation to “exercise all authority and discretion available to them to waiver, defer, grant exemptions, from, or delay” parts of the Legislation that place “unwarranted economic and regulatory burdens” on states, individuals or health care providers; (ii) directing the Department of Labor to enable the formation of health plans that would be exempt from certain Legislation essential health benefits requirements, and; (iii) eliminating cost-sharing reduction payments to insurers that would otherwise offset deductibles and other out-of-pocket expenses for health plan enrollees at or below 250 percent of the federal poverty level.  

It remains unclear what portions of the Legislation may remain, or whether any replacement or alternative programs may be created by any future legislation. Any such future repeal or replacement may have significant impact on the reimbursement for healthcare services generally, and may create reimbursement for services competing with the services offered by our hospitals. Accordingly, there can be no assurance that the adoption of any future federal or state healthcare reform legislation will not have a negative financial impact on our hospitals, including their ability to compete with alternative healthcare services funded by such potential legislation, or for our hospitals to receive payment for services;

 

there can be no assurance that if any of the announced or proposed changes described above are implemented there will not be negative financial impact on the operators of our hospitals, which material effects may include a potential decrease in the market for health care services or a decrease in the ability of the operators of our hospitals to receive reimbursement for health care services provided which could result in a material adverse effect on the financial condition or results of operations of the operators of our properties, and, thus, our business;

 

competition for our operators from other REITs;

 

the operators of our facilities face competition from other health care providers, including physician owned facilities and other competing facilities, including certain facilities operated by UHS but the real property of which is not owned by us. Such competition is experienced in markets including, but not limited to, McAllen, Texas, the site of our McAllen Medical Center, a 370-bed acute care hospital, and Riverside County, California, the site of our Southwest Healthcare System-Inland Valley Campus, a 130-bed acute care hospital;

 

changes in, or inadvertent violations of, tax laws and regulations and other factors than can affect REITs and our status as a REIT;

 

should we be unable to comply with the strict income distribution requirements applicable to REITs, utilizing only cash generated by operating activities, we would be required to generate cash from other sources which could adversely affect our financial condition;

 

our ownership interest in four LLCs/LPs in which we hold non-controlling equity interests. In addition, pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and the Trust, at any time, potentially subject to certain conditions, have the right to

18


 

 

make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member;

 

fluctuations in the value of our common stock, and;

 

other factors referenced herein or in our other filings with the Securities and Exchange Commission.

Given these uncertainties, risks and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Our actual results and financial condition, including the operating results of our lessees and the facilities leased to subsidiaries of UHS, could differ materially from those expressed in, or implied by, the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. We assume no obligation to publicly update any forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except as may be required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.

We consider our critical accounting policies to be those that require us to make significant judgments and estimates when we prepare our financial statements, including the following:

Purchase Accounting for Acquisition of Investments in Real Estate:  Purchase accounting is applied to the assets and liabilities related to all real estate investments acquired from third parties. In accordance with current accounting guidance, we account for our property acquisitions as acquisitions of assets, which permits the capitalization of acquisition costs to the underlying assets. The fair value of the real estate acquired is allocated to the acquired tangible assets, consisting primarily of land, building and tenant improvements, and identified intangible assets and liabilities, consisting of the value of above-market and below-market leases, and acquired ground leases, based in each case on their fair values. Loan premiums, in the case of above market rate loans, or loan discounts, in the case of below market loans, are recorded based on the fair value of any loans assumed in connection with acquiring the real estate.

 

The fair values of the tangible assets of an acquired property are determined based on comparable land sales for land and replacement costs adjusted for physical and market obsolescence for the improvements. The fair values of the tangible assets of an acquired property are also determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land, building and tenant improvements based on management’s determination of the relative fair values of these assets. Management determines the as-if-vacant fair value of a property based on assumptions that a market participant would use, which is similar to methods used by independent appraisers. In addition, there is intangible value related to having tenants leasing space in the purchased property, which is referred to as in-place lease value. Such value results primarily from the buyer of a leased property avoiding the costs associated with leasing the property and also avoiding rent losses and unreimbursed operating expenses during the hypothetical lease-up period. Factors considered by management in performing these analyses include an estimate of carrying costs during the expected lease-up periods considering current market conditions and costs to execute similar leases. In estimating carrying costs, management includes real estate taxes, insurance and other operating expenses and estimates of lost rental revenue during the expected lease-up periods based on current market demand. Management also estimates costs to execute similar leases including leasing commissions, tenant improvements, legal and other related costs. The value of in-place leases are amortized to expense over the remaining initial terms of the respective leases.

 

In allocating the fair value of the identified intangible assets and liabilities of an acquired property, above-market and below-market in-place lease values are recorded based on the present value (using an interest rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) estimated fair market lease rates from the perspective of a market participant for the corresponding in-place leases, measured, for above-market leases, over a period equal to the remaining non-cancelable term of the lease and, for below-market leases, over a period equal to the initial term plus any below market fixed rate renewal periods. The capitalized above-market lease values are amortized as a reduction of rental

19


 

income over the remaining non-cancelable terms of the respective leases. The capitalized below-market lease values, also referred to as acquired lease obligations, are amortized as an increase to rental income over the initial terms of the respective leases.

Asset Impairment:    We review each of our properties for indicators that its carrying amount may not be recoverable. Examples of such indicators may include a significant decrease in the market price of the property, a change in the expected holding period for the property, a significant adverse change in how the property is being used or expected to be used based on the underwriting at the time of acquisition, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of the property, or a history of operating or cash flow losses of the property. When such impairment indicators exist, we review an estimate of the future undiscounted net cash flows (excluding interest charges) expected to result from the real estate investment’s use and eventual disposition and compare that estimate to the carrying value of the property. We consider factors such as future operating income, trends and prospects, as well as the effects of leasing demand, competition and other factors. If our future undiscounted net cash flow evaluation indicates that we are unable to recover the carrying value of a real estate investment, an impairment loss is recorded to the extent that the carrying value exceeds the estimated fair value of the property. The evaluation of anticipated cash flows is highly subjective and is based in part on assumptions regarding future occupancy, rental rates and capital requirements that could differ materially from actual results in future periods. Since cash flows on properties considered to be long-lived assets to be held and used are considered on an undiscounted basis to determine whether the carrying value of a property is recoverable, our strategy of holding properties over the long-term directly decreases the likelihood of their carrying values not being recoverable and therefore requiring the recording of an impairment loss. If our strategy changes or market conditions otherwise dictate an earlier sale date, an impairment loss may be recognized and such loss could be material. If we determine that the asset fails the recoverability test, the affected assets must be reduced to their fair value.

 

We generally estimate the fair value of rental properties utilizing a discounted cash flow analysis that includes projections of future revenues, expenses and capital improvement costs that a market participant would use based on the highest and best use of the asset, which is similar to the income approach that is commonly utilized by appraisers. In certain cases, we may supplement this analysis by obtaining outside broker opinions of value or third party appraisals.

 

In considering whether to classify a property as held for sale, we consider factors such as whether management has committed to a plan to sell the property, the property is available for immediate sale in its present condition for a price that is reasonable in relation to its current value, the sale of the property is probable, and actions required for management to complete the plan indicate that it is unlikely that any significant changes will made to the plan.  If all the criteria are met, we classify the property as held for sale.  Upon being classified as held for sale, depreciation and amortization related to the property ceases and it is recorded at the lower of its carrying amount or fair value less cost to sell. The assets and related liabilities of the property are classified separately on the consolidated balance sheets for the most recent reporting period. Only those assets held for sale that constitute a strategic shift or that will have a major effect on our operations are classified as discontinued operations. 

An other than temporary impairment of an investment in an unconsolidated LLC is recognized when the carrying value of the investment is not considered recoverable based on evaluation of the severity and duration of the decline in value, including projected declines in cash flow. To the extent impairment has occurred, the excess carrying value of the asset over its estimated fair value is charged to income.

 

Federal Income Taxes:    No provision has been made for federal income tax purposes since we qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986, and intend to continue to remain so qualified.   To qualify as a REIT, we must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of our annual REIT taxable income to shareholders. As a REIT, we generally will not be subject to federal, state or local income tax on income that we distribute as dividends to our shareholders. We have historically distributed, and intend to continue to distribute, 100% of our annual REIT taxable income to our shareholders.

We are subject to a federal excise tax computed on a calendar year basis. The excise tax equals 4% of the amount by which 85% of our ordinary income plus 95% of any capital gain income for the calendar year exceeds cash distributions during the calendar year, as defined. No provision for excise tax has been reflected in the financial statements as no tax was due.

Earnings and profits, which determine the taxability of dividends to shareholders, will differ from net income reported for financial reporting purposes due to the differences for federal tax purposes in the cost basis of assets and in the estimated useful lives used to compute depreciation and the recording of provision for investment losses.

20


 

Results of Operations

During the three-month period ended June 30, 2018, net income was $5.8 million, as compared to $4.0 million during the second quarter of 2017.  The $1.8 million increase was primarily attributable to:

 

a $1.7 million increase in connection with a lease termination agreement entered into during the second quarter of 2018 in connection with a single tenant MOB located in Texas that terminated a lease that that was scheduled to expire in July, 2020;

 

a $194,000 increase resulting from hurricane-related business interruption insurance recovery proceeds recorded during the second quarter of 2018;

 

a decrease of approximately $400,000 resulting from non-recurring repairs and remediation expenses incurred at one of our medical office buildings, and;

 

other combined net increase of approximately $300,000 from increased net income generated at various properties, including the properties acquired during 2017.

During the six-month period ended June 30, 2018, net income was $15.4 million, as compared to $35.6 million during the six months of 2017.  The $20.2 million decrease was primarily attributable to:

 

a $27.2 million decrease due to a gain recorded during the first quarter of 2017 in connection with our purchase of the minority interest in, and subsequent divestiture of, the St. Mary’s Professional Office Building (“Arlington transaction”);

 

a $4.5 million increase resulting from hurricane insurance recoveries in excess of property damage write-downs recorded during the first six months of 2018;

 

a $1.2 million increase resulting from hurricane-related business interruption insurance recovery proceeds recorded during the first six months of 2018 (approximately $500,000 of which related to 2017);

 

a $1.7 million increase in connection with a lease termination agreement entered into during the second quarter of 2018, as mentioned above;

 

a $248,000 increase due to decreased interest expense resulting primarily from the repayments of eight third-party mortgages (primarily between the second quarter of 2017 through the second quarter of 2018) utilizing funds borrowed under our revolving credit agreement which bear interest at a comparatively lower interest rate, partially offset by an increase in our average cost of funds under our revolving credit agreement as compared to the six months of 2017;

 

a decrease of approximately $400,000 resulting from non-recurring repairs and remediation expenses incurred at one of our medical office buildings;

 

a $721,000 decrease in equity in income of LLCs, due primarily to the March, 2017 divestiture of St. Mary’s, and;

 

other combined net increase of approximately $500,000 due to the increased net income generated at various properties, including the properties acquired during 2017.

Included in our other operating expenses are expenses related to the consolidated medical office buildings, which totaled $4.9 million and $4.4 million for the three-month periods ended June 30, 2018 and 2017, respectively, and $9.6 million and $8.6 million for the six-month periods ended June 30, 2018 and 2017, respectively.  The increase in operating expenses during the three and six-month periods ended June 30, 2018, as compared to the prior year periods, is partially due to: (i) the newly constructed medical office building which opened in April, 2017, and; (ii) approximately $400,000 of non-recurring repairs and remediation expenses incurred at one of our medical office buildings. A large portion of the expenses associated with our consolidated medical office buildings is passed on directly to the tenants either directly as tenant reimbursements of common area maintenance expenses or included in base rental amounts. Tenant reimbursements for operating expenses are accrued as revenue in the same period the related expenses are incurred and are included as tenant reimbursement revenue in our condensed consolidated statements of income

Funds from operations (“FFO”) is a widely recognized measure of performance for Real Estate Investment Trusts (“REITs”). We believe that FFO and FFO per diluted share, which are non-GAAP financial measures, are helpful to our investors as measures of our operating performance. We compute FFO, as reflected on the attached Supplemental Schedules, in accordance with standards established by the National Association of Real Estate Investment Trusts (“NAREIT”), which may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, or that interpret the NAREIT definition differently than we interpret the definition. FFO adjusts for the effects of gains, such as gains on transactions and hurricane recovery proceeds in excess of damaged property write-downs during the periods presented.  We adjusted for hurricane insurance recovery proceeds in excess of damaged property write-downs since we believe that this gain is similar in nature and has the same characteristics as an adjustment for gains/losses resulting from the sale of depreciable property, which are required to be excluded from FFO under NAREIT’s definition. FFO does not

21


 

represent cash generated from operating activities in accordance with GAAP and should not be considered to be an alternative to net income determined in accordance with GAAP. In addition, FFO should not be used as: (i) an indication of our financial performance determined in accordance with GAAP; (ii) an alternative to cash flow from operating activities determined in accordance with GAAP; (iii) a measure of our liquidity, or; (iv) an indicator of funds available for our cash needs, including our ability to make cash distributions to shareholders.

Below is a reconciliation of our reported net income to FFO for the three and six-month periods ended June 30, 2018 and 2017 (in thousands):

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Net income

 

$

5,805

 

 

$

4,033

 

 

$

15,409

 

 

$

35,595

 

Depreciation and amortization expense on consolidated

   investments

 

 

5,959

 

 

 

6,167

 

 

 

12,110

 

 

 

12,189

 

Depreciation and amortization expense on unconsolidated

   affiliates

 

 

254

 

 

 

253

 

 

 

525

 

 

 

679

 

Hurricane insurance recovery proceeds in excess of damaged property write-downs

 

 

-

 

 

 

-

 

 

 

(4,535

)

 

 

-

 

Gain on Arlington transaction

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(27,196

)

Funds From Operations

 

$

12,018

 

 

$

10,453

 

 

$

23,509

 

 

$

21,267

 

Weighted average number of shares outstanding - Basic and Diluted

 

 

13,720

 

 

 

13,583

 

 

 

13,719

 

 

 

13,581

 

Funds From Operations per diluted share

 

$

0.88

 

 

$

0.77

 

 

$

1.71

 

 

$

1.57

 

 

Our FFO increased $1.6 million, or $.11 per diluted share, during the second quarter of 2018, as compared to the second quarter of 2017 due to: (i) an increase of $1.7 million, or $.12 per diluted share, resulting from the lease termination agreement entered into during the second quarter of 2018 in connection with a single tenant MOB located in Texas that terminated a lease that that was scheduled to expire in July, 2020; (ii) a decrease of approximately $400,000, or $.02 per diluted share, resulting from the non-recurring repairs and remediation expenses incurred at one of our medical office buildings, and; (iii) other combined net increase of approximately $300,000, or $.01 per diluted share, due to increased net income generated at various properties, including properties acquired during 2017.

 

Our FFO increased $2.2 million, or $.14 per diluted share, during the first six months of 2018, as compared to the first six months of 2017 due to: (i) an increase of $1.7 million, or $.12 per diluted share, resulting from the lease termination agreement entered into during the second quarter of 2018 in connection with a single tenant MOB located in Texas that terminated a lease that that was scheduled to expire in July, 2020; (ii) a decrease of approximately $400,000, or $.02 per diluted share, resulting from the non-recurring repairs and remediation expenses incurred at one of our medical office buildings; (iii) an increase of approximately $500,000, or $.04 per diluted share, resulting for business interruption insurance recovery proceeds recording during the first six months of 2018 that related to the period of August through December of 2017, and; (iv) other combined net increase of approximately $400,000 due to increased net income generated at various properties, including properties acquired during 2017.

 

Hurricane Harvey Impact

In late August, 2017, five of our medical office buildings located in the Houston, Texas area, as mentioned below, incurred extensive water damage as a result of Hurricane Harvey. Until various times during the second quarter of 2018, these properties were temporarily closed and non-operational as we continued to reconstruct and restore them to operational condition. As of June 30, 2018, reconstruction on all of the occupied space in these properties has been completed and operations have resumed.

 

During the first quarter of 2018, pursuant to the terms of a global settlement with our commercial property insurance carrier, we received $5.5 million of additional insurance recovery proceeds bringing the aggregate hurricane-related insurance recoveries to $12.5 million. The aggregate insurance recovery proceeds, which are net of applicable deductibles, covered substantially all of the costs incurred related to the remediation, repair and reconstruction of each of these properties as well business interruption recoveries for the lost income related to each of these properties during the period they were non-operational.  

 

Our properties damaged and temporarily closed from Hurricane Harvey were:

 

Cypresswood Professional Center – located in Spring, Texas and consisting of two medical office buildings (“MOBs”) with an aggregate of approximately 40,000 rentable square feet.

22


 

 

Professional Buildings at King’s Crossing – located in Kingwood, Texas and consisting of two MOBs with an aggregate of approximately 24,300 rentable square feet.

 

Kelsey-Seybold Clinic at King’s Crossing – located in Kingwood, Texas and consisting of one MOB with approximately 20,500 rentable square feet.

 

Liquidity and Capital Resources

Net cash provided by operating activities

Net cash provided by operating activities was $23.2 million during the six-month period ended June 30, 2018 as compared to $20.3 million during the comparable period of 2017. The $2.9 million net increase was attributable to:  

 

a favorable net change of $2.4 million due to an increase in net income plus/minus the adjustments to reconcile net income to net cash provided by operating activities (depreciation and amortization, amortization of debt premium, stock-based compensation, hurricane insurance recovery proceeds in excess of damaged property write-downs, and gain on Arlington transaction);

 

a favorable change of $634,000 in tenant reserves, deposits and deferred and prepaid rents;

•     a favorable change of $346,000 in rent receivable;

•     an unfavorable change of $194,000 in leasing costs paid, and;

•     other combined net unfavorable change of approximately $300,000.

Net cash used in/provided by investing activities

Net cash used in investing activities was $3.8 million during the first six months of 2018 as compared to $51.1 million of net cash provided by investing activities during the first six months of 2017.

During the six-month period ended June 30, 2018, we funded: (i) $369,000 in equity investments in an unconsolidated LLC; (ii) $4.2 million in capital additions to real estate investments including tenant improvements at various MOBs; (iii) $4.1 million paid to acquire the Beaumont Medical Sleep Center Building, as discussed above, and; (iv) $192,000 of hurricane related remediation expenses  In addition, during the six-month period ended June 30, 2018, we received: (i) $4.5 million of hurricane insurance proceeds in excess of damaged property write-downs, and; (ii) $501,000 of cash distributions in excess of income received from our unconsolidated LLCs.      

During the six-month period ended June 30, 2017, we funded: (i) $532,000 million in equity investments in various unconsolidated LLCs; (ii) $6.5 million in capital additions to real estate investments including construction costs for the Henderson Medical Plaza MOB (this MOB opened in April, 2017), as well as tenant improvements at various MOBs; (iii) $7.9 million paid to acquire the minority interest in a majority-owned LLC (Arlington Medical Properties), and; (iv) $150,000 deposit on real estate assets in connection with the July, 2017 acquisition of the Healthcare Center at Hamburg. In addition, during the six-month period ended June 30, 2017, we received: (i) $54.0 million of net cash proceeds received in connection with the divestiture of St. Mary’s Professional Office Building (net of closing costs and $11.3 million of restricted cash held by a 1031 exchange intermediary, as discussed below); (ii) $216,000 of installment repayments of an outstanding member loan that was provided by us to Arlington Medical Properties, LLC, and; (iii) $743,000 of cash distributions in excess of income received from our unconsolidated LLCs.  Additionally, as a result of our January 1, 2018 adoption of ASU 2016-18, Restricted Cash, we recognized $11.3 million of restricted cash proceeds during the six-month period ended June 30, 2017 in connection with the divestiture of St. Mary’s Professional Office Building. This restricted cash was held until the third quarter of 2017 at which time the majority of the cash was utilized to fund planned like-kind exchange acquisitions pursuant to Section 1031 of the IRS code.

Net cash used in financing activities

Net cash used in financing activities was $17.0 million during the six months ended June 30, 2018, as compared to $60.0 million during the six months ended June 30, 2017.

During the six-month period ended June 30, 2018, we paid: (i) $22.6 million on mortgage notes payable that are non-recourse to us, including the repayments of $21.7 million related to previously outstanding mortgage notes payable on three properties, which were funded utilizing borrowings under our revolving credit agreement; (ii) $1.5 million of financing costs related to the revolving credit agreement that was amended during the first quarter of 2018, and; (iii) $9.2 million of dividends (excludes the $9.2 million dividend declared on June 13, 2018 that was paid on July 3, 2018). Additionally, during the six months ended June 30, 2018, we received: (i) $16.2 million of net borrowings on our revolving credit agreement, and; (ii) $60,000 of net cash from the issuance of shares of beneficial interest.

23


 

During the six-month period ended June 30, 2017, we paid: (i) $18.7 million of net borrowings on our revolving line of credit; (ii) $36.5 million on mortgage notes payable that are non-recourse to us, including the repayment of an aggregate of $35.0 million related to previously outstanding mortgage notes payable on three properties that were funded utilizing borrowings under our revolving credit facility; (iii) $284,000 of financing costs related to the revolving credit facility and a mortgage note payable that is non-recourse to us, and; (iv) $17.9 million of dividends.  Additionally, during the six months ended June 30, 2017, we received (i) $13.2 million of proceeds from a new mortgage note payable that is non-recourse to us (these proceeds were utilized to repay outstanding borrowings under our revolving credit facility), and; (ii) $122,000 of net cash from the issuance of shares of beneficial interest.

Additional cash flow and dividends paid information for the six-month periods ended June 30, 2018 and 2017:

As indicated on our condensed consolidated statement of cash flows, we generated net cash provided by operating activities of $23.2 million and $20.3 million during the six-month periods ended June 30, 2018 and 2017, respectively. As also indicated on our statement of cash flows, non-cash expenses including depreciation and amortization expense, amortization of debt premium, stock-based compensation expense, hurricane insurance recovery proceeds in excess of damaged property write-downs and gain on transaction (as applicable) are the primary differences between our net income and net cash provided by operating activities during each period. In addition, as reflected in the cash flows from investing activities section, we received $501,000 and $734,000 during the six-month periods ended June 30, 2018 and 2017, respectively, of cash distributions in excess of income from various unconsolidated LLCs which represents our share of the net cash flow distributions from these entities. The cash distributions in excess of income represent operating cash flows net of capital expenditures and debt repayments made by the LLCs.

We therefore generated $23.7 million and $21.1 million of net cash during the six months ended June 30, 2018 and 2017, respectively, related to the operating activities of our properties recorded on a consolidated and an unconsolidated basis. We declared dividends of $18.3 million during the six months ended June 30, 2018 ($9.2 million of which was paid in July, 2018) and declared and paid dividends of $17.9 million during the six months ended June 30, 2017. During the first six months of 2018, the $23.7 million of net cash generated related to the operating activities of our properties was approximately $5.4 million greater than the $18.3 million of dividends declared during the first six months of 2018. During the first six months of 2017, the $21.1 million of net cash generated related to the operating activities of our properties was approximately $3.2 million greater than the $17.9 million of dividends declared and paid during the first six months of 2017.  

As indicated in the cash flows from investing activities and cash flows from financing activities sections of the statements of cash flows, there were various other sources and uses of cash during the six months ended June 30, 2018 and 2017.  From time to time, various other sources and uses of cash may include items such as investments and advances made to/from LLCs, additions to real estate investments, acquisitions/divestiture of properties, net borrowings/repayments of debt, and proceeds generated from the issuance of equity. Therefore, in any given period, the funding source for our dividend payments is not wholly dependent on the operating cash flow generated by our properties. Rather, our dividends as well as our capital reinvestments into our existing properties, acquisitions of real property and other investments are funded based upon the aggregate net cash inflows or outflows from all sources and uses of cash from the properties we own either in whole or through LLCs, as outlined above.

In determining and monitoring our dividend level on a quarterly basis, our management and Board of Trustees consider many factors in determining the amount of dividends to be paid each period. These considerations primarily include: (i) the minimum required amount of dividends to be paid in order to maintain our REIT status; (ii) the current and projected operating results of our properties, including those owned in LLCs, and; (iii) our future capital commitments and debt repayments, including those of our LLCs. Based upon the information discussed above, as well as consideration of projections and forecasts of our future operating cash flows, management and the Board of Trustees have determined that our operating cash flows have been sufficient to fund our dividend payments. Future dividend levels will be determined based upon the factors outlined above with consideration given to our projected future results of operations.

We expect to finance all capital expenditures and acquisitions and pay dividends utilizing internally generated and additional funds. Additional funds may be obtained through: (i) borrowings under our existing $300 million revolving credit agreement (which had $102.7 million of available borrowing capacity, net of outstanding borrowings as of June 30, 2018); (ii) borrowings under or refinancing of existing third-party debt pursuant to mortgage loan agreements entered into by our consolidated and unconsolidated LLCs/LPs; (iii) the issuance of equity, and/or; (iv) the issuance of other long-term debt.

We believe that our operating cash flows, cash and cash equivalents, available borrowing capacity under our revolving credit agreement and access to the capital markets provide us with sufficient capital resources to fund our operating, investing and financing requirements for the next twelve months, including providing sufficient capital to allow us to make distributions necessary to enable us to continue to qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986. In the event we need to access the capital markets or other sources of financing, there can be no assurance that we will be able to obtain financing on acceptable terms or within an acceptable time. Our inability to obtain financing on terms acceptable to us could have a material unfavorable impact on our results of operations, financial condition and liquidity.

24


 

Credit facilities and mortgage debt

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $300 million revolving credit agreement, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On March 27, 2018, we entered into a revolving credit agreement (“Credit Agreement”) which, among other things, increased our borrowing capacity by $50 million to $300 million and extended the maturity date from our previously existing facility. The replacement Credit Agreement, which is scheduled to mature in March, 2022, includes a $40 million sublimit for letters of credit and a $30 million sub limit for swingline/short-term loans.  The Credit Agreement also provides for options to extend the maturity date for two additional six month periods. Additionally, the Credit Agreement includes an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement.  Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines “Base Rate” as the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At June 30, 2018, the applicable margin over the LIBOR rate was 1.15%, the margin over the Base Rate was 0.15%, and the facility fee was 0.20%.  

At June 30, 2018, we had $197.3 million of outstanding borrowings under our Credit Agreement and $102.7 million of available borrowing capacity.  There are no compensating balance requirements.  As disclosed below, during the first six months of 2018, we repaid an aggregate of $21.7 million on three mortgages utilizing borrowings under our Credit Agreement.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at June 30, 2018. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands): 

 

 

Covenant

 

June 30,

2018

 

Tangible net worth

 

> =$125,000

 

$

188,737

 

Total leverage

 

< 60%

 

 

39.9

%

Secured leverage

 

< 30%

 

 

8.1

%

Unencumbered leverage

 

< 60%

 

 

36.2

%

Fixed charge coverage

 

> 1.50x

 

4.1x

 

 

25


 

As indicated on the following table, we have eight mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of June 30, 2018 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

$

2,573

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

5,961

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,028

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,877

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,940

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

13,198

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

4,273

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

9,307

 

 

 

3.95

%

 

January, 2030

Total, excluding net debt premium and net financing fees

 

 

53,157

 

 

 

 

 

 

 

     Less net financing fees

 

 

(625

)

 

 

 

 

 

 

     Plus net debt premium

 

 

274

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

52,806

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

On February 13, 2018, upon its maturity, a $4.1 million floating rate mortgage loan on the Sparks Medical Building/Vista Medical Terrace was fully repaid utilizing borrowings under our Credit Agreement.  

On April 5, 2018, upon its maturity, a $9.7 million floating rate mortgage loan on the Centennial Hills Medical Office Building was fully repaid utilizing borrowings under our Credit Agreement.  

On May 2, 2018, upon its maturity, a $7.9 million fixed rate mortgage loan on the Rosenberg Children’s Medical Plaza was fully repaid utilizing borrowings under our Credit Agreement.  

The mortgages are secured by the real property of the buildings as well as property leases and rents. The eight mortgages outstanding as of June 30, 2018 had a combined fair value of approximately $53.0 million. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

At December 31, 2017, we had eleven mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these eleven mortgages was $75.7 million and had a combined fair value of approximately $76.3 million.

 

Off Balance Sheet Arrangements

As of June 30, 2018, we do not have any off balance sheet arrangements other than equity and debt financing commitments.   

Acquisition and Divestiture Activity

Please see Note 4 to the condensed consolidated financial statements for completed transactions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Reference is made to Item 7A in our Annual Report on Form 10-K for the year ended December 31, 2017. There have been no material changes in the quantitative and qualitative disclosures during the first six months of 2018.

26


 

Item 4. Controls and Procedures

As of June 30, 2018, under the supervision and with the participation of our management, including the Trust’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), we performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “1934 Act”).

Based on this evaluation, the CEO and CFO have concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the 1934 Act and the SEC rules thereunder.

There have been no changes in our internal control over financial reporting or in other factors during the first six months of 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

27


 

PART II. OTHER INFORMATION

UNIVERSAL HEALTH REALTY INCOME TRUST

Item 1A. Risk Factors

Our Annual Report on Form 10-K for the year ended December 31, 2017 includes a listing of risk factors to be considered by investors in our securities. There have been no material changes in our risk factors from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2017.

Item 6. Exhibits

(a.) Exhibits:

 

  31.1

 

Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  31.2

 

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  32.1

 

Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

  32.2

 

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

 

 

28


 

EXHIBIT INDEX

 

Exhibit

No.

 

Description

 

 

 

  31.1

 

Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  31.2

 

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  32.1

 

Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

  32.2

 

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

29


 

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: August 8, 2018

 

UNIVERSAL HEALTH REALTY INCOME TRUST

(Registrant)

 

 

 

 

 

/s/ Alan B. Miller 

 

 

Alan B. Miller,

 

 

Chairman of the Board,

President and Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 

/s/ Charles F. Boyle 

 

 

Charles F. Boyle, Vice President and Chief Financial Officer

(Principal Financial Officer)

 

30

EX-31.1 2 uht-ex311_9.htm EX-31.1 uht-ex311_9.htm

 

Exhibit 31.1

CERTIFICATION—Chief Executive Officer

I, Alan B. Miller, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2018

 

/s/ Alan B. Miller 

President and Chief Executive Officer

 

 

EX-31.2 3 uht-ex312_8.htm EX-31.2 uht-ex312_8.htm

 

Exhibit 31.2

CERTIFICATION—Chief Financial Officer

I, Charles F. Boyle, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 8, 2018

 

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

 

 

EX-32.1 4 uht-ex321_6.htm EX-32.1 uht-ex321_6.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended June 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan B. Miller, President and Chief Executive Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

 

/s/ Alan B. Miller

President and Chief Executive Officer

August 8, 2018

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-32.2 5 uht-ex322_7.htm EX-32.2 uht-ex322_7.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended June 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles F. Boyle, Vice President and Chief Financial Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

 

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

August 8, 2018

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-101.INS 6 uht-20180630.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure uht:Property uht:Time uht:RenewalOption uht:Acquisition uht:Option uht:MortgageLoan uht:Derivative uht:Segment uht:Building 0000798783 2018-01-01 2018-06-30 0000798783 2018-07-31 0000798783 uht:UniversalHealthServicesIncMember 2018-04-01 2018-06-30 0000798783 uht:UniversalHealthServicesIncMember 2017-04-01 2017-06-30 0000798783 uht:UniversalHealthServicesIncMember 2018-01-01 2018-06-30 0000798783 uht:UniversalHealthServicesIncMember 2017-01-01 2017-06-30 0000798783 2018-04-01 2018-06-30 0000798783 2017-04-01 2017-06-30 0000798783 2017-01-01 2017-06-30 0000798783 uht:TenantReimbursementsAndOtherMember uht:NonRelatedPartyMember 2018-04-01 2018-06-30 0000798783 uht:TenantReimbursementsAndOtherMember uht:NonRelatedPartyMember 2017-04-01 2017-06-30 0000798783 uht:TenantReimbursementsAndOtherMember uht:NonRelatedPartyMember 2018-01-01 2018-06-30 0000798783 uht:TenantReimbursementsAndOtherMember uht:NonRelatedPartyMember 2017-01-01 2017-06-30 0000798783 uht:TenantReimbursementsAndOtherMember uht:UniversalHealthServicesIncMember 2018-04-01 2018-06-30 0000798783 uht:TenantReimbursementsAndOtherMember uht:UniversalHealthServicesIncMember 2017-04-01 2017-06-30 0000798783 uht:TenantReimbursementsAndOtherMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-06-30 0000798783 uht:TenantReimbursementsAndOtherMember uht:UniversalHealthServicesIncMember 2017-01-01 2017-06-30 0000798783 us-gaap:ManagementServiceMember 2018-04-01 2018-06-30 0000798783 us-gaap:ManagementServiceMember 2017-04-01 2017-06-30 0000798783 us-gaap:ManagementServiceMember 2018-01-01 2018-06-30 0000798783 us-gaap:ManagementServiceMember 2017-01-01 2017-06-30 0000798783 2018-06-30 0000798783 2017-12-31 0000798783 2016-12-31 0000798783 2017-06-30 0000798783 srt:MinimumMember uht:UnconsolidatedLimitedLiabilitiesMember 2018-06-30 0000798783 srt:MaximumMember uht:UnconsolidatedLimitedLiabilitiesMember 2018-06-30 0000798783 uht:MedicalOfficeBuildingsMember uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2018-06-30 0000798783 uht:UniversalHealthServicesIncMember srt:MinimumMember 2018-01-01 2018-06-30 0000798783 uht:UniversalHealthServicesIncMember srt:MaximumMember 2018-01-01 2018-06-30 0000798783 uht:UniversalHealthServicesIncMember 2018-06-30 0000798783 uht:UniversalHealthServicesIncMember us-gaap:AssetsLeasedToOthersMember 2018-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2018-04-01 2018-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2017-04-01 2017-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2017-01-01 2017-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2018-04-01 2018-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2017-04-01 2017-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2018-01-01 2018-06-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2017-01-01 2017-06-30 0000798783 uht:UniversalHealthServicesIncMember uht:McAllenMedicalCenterMember 2018-06-01 2018-06-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2018-06-30 0000798783 uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2018-06-30 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2018-06-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-06-30 0000798783 uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-06-30 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-06-30 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-06-30 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember srt:MinimumMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-06-30 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember srt:MaximumMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-06-30 0000798783 uht:HendersonMedicalPlazaMember uht:UniversalHealthServicesIncMember 2017-04-01 2017-04-30 0000798783 uht:HendersonMedicalPlazaMember uht:UniversalHealthServicesIncMember 2017-04-30 0000798783 uht:HendersonMedicalPlazaMember uht:UniversalHealthServicesIncMember 2018-06-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2018-06-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember srt:MinimumMember 2018-06-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2018-01-01 2018-06-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2017-01-01 2017-06-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember us-gaap:ManagementServiceMember 2018-04-01 2018-06-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember us-gaap:ManagementServiceMember 2017-04-01 2017-06-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember us-gaap:ManagementServiceMember 2018-01-01 2018-06-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember us-gaap:ManagementServiceMember 2017-01-01 2017-06-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2018-04-01 2018-06-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2017-04-01 2017-06-30 0000798783 uht:UniversalHealthServicesIncMember 2017-12-31 0000798783 us-gaap:SubsequentEventMember 2018-07-02 2018-07-03 0000798783 uht:BeaumontMedicalSleepCenterBuildingMember 2018-01-01 2018-06-30 0000798783 uht:BeaumontMedicalSleepCenterBuildingMember 2018-06-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2017-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2017-03-12 0000798783 uht:ArlingtonMedicalPropertiesMember 2017-03-01 2017-03-31 0000798783 uht:SaintMarysProfessionalOfficeBuildingMember 2017-03-31 0000798783 2017-01-01 2017-03-31 0000798783 uht:SaintMarysProfessionalOfficeBuildingMember 2017-01-03 2017-09-30 0000798783 uht:SaintMarysProfessionalOfficeBuildingMember 2017-01-01 2017-06-30 0000798783 srt:MinimumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2018-06-30 0000798783 srt:MaximumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2018-06-30 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2018-06-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2018-06-30 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2018-06-30 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2018-06-30 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2018-01-01 2018-06-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2018-01-01 2018-06-30 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2018-01-01 2018-06-30 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2018-01-01 2018-06-30 0000798783 uht:BrunswickAssociatesMember 2018-06-30 0000798783 uht:GraysonPropertiesMember 2018-06-30 0000798783 uht:FTXMobPhaseTwoLPMember 2018-06-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2017-01-01 2017-06-30 0000798783 uht:ArlingtonMedicalPropertiesMember 2018-01-01 2018-06-30 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FTXMobPhaseTwoMember 2018-06-30 0000798783 us-gaap:EquityMethodInvestmentsMember 2018-06-30 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FTXMobPhaseTwoMember 2017-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesMember 2017-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:BrunswickAssociatesMember 2017-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2017-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FTXMobPhaseTwoMember 2018-01-01 2018-06-30 0000798783 uht:FivePointZeroZeroPercentFixedRateMortgageLoanMember uht:FTXMobPhaseTwoMember 2018-06-30 0000798783 uht:FivePointZeroThreeFourPercentFixedRateMortgageLoanMember uht:GraysonPropertiesMember 2018-06-30 0000798783 uht:ThreePointSixFourPercentFixedRateMortgageLoanMember uht:BrunswickAssociatesMember 2018-06-30 0000798783 srt:MinimumMember 2018-01-01 2018-06-30 0000798783 srt:MaximumMember 2018-01-01 2018-06-30 0000798783 us-gaap:AccountingStandardsUpdate201409Member 2018-06-30 0000798783 us-gaap:AccountingStandardsUpdate201409Member uht:TenantReimbursementsAndOtherPropertyIncomeMember 2018-04-01 2018-06-30 0000798783 us-gaap:AccountingStandardsUpdate201409Member uht:TenantReimbursementsAndOtherPropertyIncomeMember 2017-04-01 2017-06-30 0000798783 us-gaap:AccountingStandardsUpdate201409Member uht:TenantReimbursementsAndOtherPropertyIncomeMember 2018-01-01 2018-06-30 0000798783 us-gaap:AccountingStandardsUpdate201409Member uht:TenantReimbursementsAndOtherPropertyIncomeMember 2017-01-01 2017-06-30 0000798783 us-gaap:AccountingStandardsUpdate201409Member 2018-04-01 2018-06-30 0000798783 uht:RevolvingCreditAgreementMember 2018-06-30 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LetterOfCreditMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:ShortTermDebtMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember 2018-01-01 2018-06-30 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:BaseRateMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:BaseRateMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember uht:FederalFundsEffectiveRateMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-06-30 0000798783 uht:RevolvingCreditAgreementMember us-gaap:BaseRateMember 2018-01-01 2018-06-30 0000798783 uht:ThreeMortgagesUtilizingBorrowingsUnderCreditAgreementMember 2018-01-01 2018-06-30 0000798783 srt:MaximumMember 2018-06-30 0000798783 uht:VibraHospitalOfCorpusChristiFixedRateMortgageLoanMember 2018-06-30 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingMortgageLoanMember 2018-06-30 0000798783 uht:BRBMedicalOfficeBuildingMortgageLoanMember 2018-06-30 0000798783 uht:DesertValleyMedicalCenterFloatingRateMortgageLoanMember 2018-06-30 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2018-06-30 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2018-06-30 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2018-06-30 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2018-06-30 0000798783 uht:VibraHospitalOfCorpusChristiFixedRateMortgageLoanMember 2018-01-01 2018-06-30 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingMortgageLoanMember 2018-01-01 2018-06-30 0000798783 uht:BRBMedicalOfficeBuildingMortgageLoanMember 2018-01-01 2018-06-30 0000798783 uht:DesertValleyMedicalCenterFloatingRateMortgageLoanMember 2018-01-01 2018-06-30 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2018-01-01 2018-06-30 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2018-01-01 2018-06-30 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2018-01-01 2018-06-30 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2018-01-01 2018-06-30 0000798783 uht:LomaVistaMedicalIncMember 2018-02-12 2018-02-13 0000798783 uht:CentennialHillsMedicalOfficeBuildingOneMortgageLoanMember 2018-04-04 2018-04-05 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2018-05-01 2018-05-02 0000798783 us-gaap:InterestRateCapMember 2016-06-30 0000798783 us-gaap:InterestRateCapMember 2016-09-30 0000798783 us-gaap:InterestRateCapMember 2016-04-01 2016-06-30 0000798783 us-gaap:InterestRateCapMember 2016-07-01 2016-09-30 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:InterestRateCapMember 2016-06-30 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:InterestRateCapMember 2016-09-30 0000798783 us-gaap:InterestRateCapMember 2016-04-01 2018-06-30 0000798783 us-gaap:InterestRateCapMember 2016-07-01 2018-06-30 0000798783 uht:HoustonTexasMember uht:HurricaneHarveyExtensiveWaterDamageMember 2017-08-31 0000798783 uht:HurricaneHarveyMember 2018-01-01 2018-06-30 0000798783 uht:BusinessInterruptionMember uht:HurricaneHarveyMember 2017-09-01 2018-06-30 0000798783 uht:BusinessInterruptionMember uht:HurricaneHarveyMember 2018-04-01 2018-06-30 0000798783 uht:TwoThousandSeventeenBusinessInterruptionMember uht:HurricaneHarveyMember 2017-09-01 2017-12-31 0000798783 uht:BusinessInterruptionMember uht:HurricaneHarveyMember 2018-01-01 2018-06-30 0000798783 uht:SpringTexasMember uht:PropertiesDamagedAndTemporarilyClosedFromHurricaneHarveyMember uht:CypresswoodProfessionalCenterMember 2017-08-31 0000798783 uht:KingwoodTexasMember uht:PropertiesDamagedAndTemporarilyClosedFromHurricaneHarveyMember uht:ProfessionalBuildingsAtKingsCrossingMember 2017-08-31 0000798783 uht:KingwoodTexasMember uht:PropertiesDamagedAndTemporarilyClosedFromHurricaneHarveyMember uht:KelseySeyboldClinicAtKingsCrossingMember 2017-08-31 10-Q false 2018-06-30 2018 Q2 UHT UNIVERSAL HEALTH REALTY INCOME TRUST 0000798783 --12-31 Large Accelerated Filer 13745138 4187000 4303000 8363000 8383000 10217000 10116000 20544000 20086000 1204000 1242000 2530000 2530000 4200000 2239000 6615000 4432000 303000 245000 598000 464000 20111000 18145000 38650000 35895000 6111000 6295000 12398000 12440000 948000 874000 1852000 1740000 5445000 4923000 10653000 9628000 56000 126000 12504000 12148000 24903000 23934000 7607000 5997000 13747000 11961000 425000 498000 854000 1575000 4535000 194000 1162000 27196000 -2421000 -2462000 -4889000 -5137000 5805000 4033000 15409000 35595000 0.42 0.30 1.12 2.62 0.42 0.30 1.12 2.62 13720000 13583000 13719000 13581000 6000 -75000 154000 -93000 6000 -75000 154000 -93000 5811000 3958000 15563000 35502000 553970000 546634000 163434000 153379000 390536000 393255000 53396000 53142000 443932000 446397000 4655000 4671000 5732000 3387000 2610000 2680000 6829000 6422000 19253000 20559000 7991000 5892000 491002000 490008000 197250000 181050000 52806000 75359000 504000 540000 12193000 12188000 9156000 11103000 10310000 283012000 279447000 137000 137000 265544000 265335000 633529000 618120000 691518000 673175000 298000 144000 207990000 210561000 491002000 490008000 25700000 28700000 0.01 0.01 5000000 5000000 0 0 0 0 0.01 0.01 95000000 95000000 13744229 13735369 13744229 13735369 15409000 35595000 12288000 12476000 -23000 -100000 254000 252000 337000 683000 -445000 -398000 713000 79000 36000 62000 597000 403000 -517000 -783000 23208000 20343000 369000 532000 216000 501000 734000 -4246000 -6537000 53967000 11253000 4535000 192000 150000 4053000 7890000 -3824000 51061000 16200000 -18650000 22585000 36473000 13200000 1527000 284000 9187000 17887000 60000 122000 -17039000 -59972000 2345000 11432000 3387000 3930000 5732000 15362000 4711000 5039000 <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) General</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q is for the quarter ended June 30, 2018. In this Quarterly Report, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Trust&#8221; refer to Universal Health Realty Income Trust and its subsidiaries.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this Quarterly Report on Form 10-Q, the term &#8220;revenues&#8221; does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.&nbsp;&nbsp;As of June 30, 2018, we had investments in four jointly-owned LLCs/LPs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December&#160;31, 2017.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Certain prior period amounts on our statement of cash flows have been reclassified to conform to the current period presentation in connection with our adoption of ASU No. 2016-18, <font style="font-style:italic;">Restricted Cash</font>. </p></div> <div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) Relationship with Universal Health Services, Inc. (&#8220;UHS&#8221;) and Related Party Transactions</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases:<font style="font-style:normal;">&#160;We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each of the three hospital facilities leased to subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 20% and 22% of our consolidated revenues for the three months ended June 30, 2018 and 2017, respectively, and approximately 21% and 23% of our consolidated revenues for the six months ended June 30, 2018 and 2017, respectively. In addition, we have seventeen medical office buildings (&#8220;MOBs&#8221;), or&#160;free-standing emergency departments (&#8220;FEDs&#8221;), that are either wholly or jointly-owned by us, that include tenants which are subsidiaries of UHS.&nbsp;&nbsp;The aggregate revenues generated from UHS-related tenants comprised approximately 28% and 32% of our consolidated revenues during the three-month periods ended June 30, 2018 and 2017, respectively, and approximately 30% and 32% of our consolidated revenues during the six-month periods ended June 30, 2018 and 2017, respectively. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December&#160;24, 1986 (the &#8220;Master Lease&#8221;), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month&#8217;s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i)&#160;purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii)&#160;renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June, 2018, McAllen Medical Center, a wholly-owned subsidiary of UHS, provided notice to us, exercising the 5-year renewal option on their lease.&nbsp;&nbsp;The renewal extended the lease term on this facility, at the existing lease rate, to December, 2026.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Hospital Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2026</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has one 5-year renewal option at the existing lease rate (through 2031).</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.&nbsp;&nbsp;</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April, 2017, the recently constructed Henderson Medical Plaza MOB received its certificate of occupancy. Henderson Medical Plaza is located on the campus of the Henderson Hospital Medical Center, a newly constructed acute care hospital that is owned and operated by a subsidiary of UHS and was completed and opened during the fourth quarter of 2016.&nbsp;&nbsp;A ground lease has been executed between the limited liability company that owns the MOB and a subsidiary of UHS, the terms of which include a seventy-five year lease term with two, ten-year renewal options at the lessee&#8217;s option at an adjusting lease rate. We have invested net cash of approximately $13.0 million on the development and construction of this MOB as of June 30, 2018.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Advisory Agreement:&#160;&#160;&#160;&#160;<font style="font-style:normal;">UHS of Delaware, Inc. (the &#8220;Advisor&#8221;), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the &#8220;Advisory Agreement&#8221;) dated December&#160;24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the &#8220;Independent Trustees&#8221;). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December&#160;31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor&#8217;s performance has been satisfactory. Our advisory fee is 0.70% of our average invested real estate assets, as derived from our consolidated balance sheet. In December of 2017, based upon a review of our advisory fee and other general and administrative expenses as compared to an industry peer group, the Advisory Agreement was renewed for 2018 pursuant to the same terms as the Advisory Agreement in place since 2013.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid at any time since our inception since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $948,000 and $874,000 for the three months ended June 30, 2018 and 2017, respectively, and were based upon average invested real estate assets of $542&#160;million and $499 million for the three-month periods ended June 30, 2018 and 2017, respectively.&nbsp;&nbsp;Advisory fees incurred and paid (or payable) to UHS amounted to $1.9 million and $1.7 million for the six months ended June 30, 2018 and 2017, respectively, and were based upon average invested real estate assets of $529&#160;million and $497 million for the six-month periods ended June 30, 2018 and 2017, respectively</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Officers and Employees:<font style="font-style:normal;"> Our officers are all employees of a wholly-owned subsidiary of UHS and although as of June 30, 2018 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share Ownership:<font style="font-style:normal;"> At each of June&#160;30, 2018 and December&#160;31, 2017, UHS owned 5.7%, of our outstanding shares of beneficial interest.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">SEC reporting requirements of UHS:<font style="font-style:normal;"> UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 28% and 32% of our consolidated revenues during the three-month periods ended June 30, 2018 and 2017, respectively, and 30% and 32% of our consolidated revenues during the six-month periods ended June 30, 2018 and 2017, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC&#8217;s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.</font></p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(3) Dividends </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We declared dividends of $9.2 million, or $.67 per share, during the second quarter of 2018, which were paid on July 3, 2018.&nbsp;&nbsp;We declared and paid dividends of $9.0 million, or $.66 per share, during the second quarter of 2017. During the six-month period ended June 30, 2018, we declared dividends of $18.3 million, or $1.335 per share, $9.2 million of which was paid on July 3, 2018. We declared and paid dividends of $17.9 million, or $1.315 per share, during the six-month period ended June 30, 2017. </p></div> <div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) Acquisitions and Dispositions</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June&#160;30, 2018:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acquisitions:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June, 2018, we acquired the Beaumont Medical Sleep Center Building located in Southfield, Michigan for a purchase price of approximately $4.0 million.&nbsp;&nbsp;This building is 100% leased under the terms of a triple net lease with a remaining initial lease term of approximately 9.5 years at the time of purchase, with two, five year renewal options. </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dispositions:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no dispositions during the first six months of 2018.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30, 2017:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acquisitions:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;There were no acquisitions during the first six months of 2017.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Disposition:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During March, 2017, Arlington Medical Properties, LLC, a formerly jointly-owned limited liability company in which we held an 85% noncontrolling ownership interest, sold the real estate assets of St. Mary&#8217;s Professional Office Building (&#8220;St. Mary&#8217;s&#8221;) as part of a series of planned tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.&nbsp;&nbsp;St. Mary&#8217;s is a multi-tenant medical office building located in Reno, Nevada.&nbsp;&nbsp;A third party member owned the remaining 15% of Arlington Medical Properties LLC, which we acquired prior to the divestiture of St. Mary&#8217;s for a purchase price of $7.9 million. The divestiture of St. Mary&#8217;s generated an aggregate of approximately $57.3 million of net cash proceeds to us (approximately $11.3 million of which was held as restricted cash by a qualified 1031 exchange intermediary until the third quarter of 2017).&nbsp;&nbsp;These proceeds, which were net of closing costs and the purchase price paid for the minority member&#8217;s ownership interest in the LLC, include repayment to us of a $21.4 million member loan.&nbsp;&nbsp;Our results of operations for the six-month period ended June 30, 2017 included a net gain of $27.2 million (net of related transaction costs) recorded in connection with this transaction.</p></div> <div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(5) Summarized Financial Information of Equity Affiliates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method.&nbsp;&nbsp;The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i)&#160;divestiture of property; (ii)&#160;annual budget approval, and; (iii)&#160;financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the Condensed Consolidated Statements of Cash Flows, distributions and equity in net income are presented net as cash flows from operating activities. Cumulative distributions received exceeding cumulative equity in earnings represent returns of investments and are classified as cash flows from investing activities in the Condensed Consolidated Statements of Cash Flows.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 2018, we have non-controlling equity investments or commitments in four jointly-owned LLCs/LPs which own MOBs. As of June 30, 2018, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The following property table represents the four LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of June&#160;30, 2018:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC/LP</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (b.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (c.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</p></td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of June 30, 2018.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of June 30, 2018.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of June 30, 2018.&nbsp;&nbsp;This LP has a third-party term loan, which is non-recourse to us, of $5.1 million outstanding as of June&#160;30, 2018.</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined statements of income (unaudited) for the LLCs/LPs accounted for under the equity method during the three and six months ended June 30, 2018 and 2017.&nbsp;&nbsp;The six months ended June 30, 2017 include the financial results of Arlington Medical Properties, LLC, through the March 13, 2017 divestiture date.&nbsp;&nbsp; </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.32%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,451</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,410</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,913</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,993</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">977</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">939</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,935</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,189</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">438</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">895</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,064</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">656</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">899</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">708</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,427</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,841</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">425</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">854</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,575</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our share of net income for the six months ended June 30, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC.&nbsp;&nbsp;This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.&nbsp;&nbsp; </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs that were accounted for under the equity method as of June 30, 2018 and December 31, 2017:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including construction in progress</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,345</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,111</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,659</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,560</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,004</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,671</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,654</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,067</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,548</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,839</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,802</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,765</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,004</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,671</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in LLCs before amounts included in</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,655</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,671</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Amounts included in accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,011</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,895</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in LLCs, net</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,644</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,776</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2018, and December&#160;31, 2017, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6/30/2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (5.00% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,134</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,202</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October, 2020</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (5.034% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,060</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,191</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (3.64% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,354</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,446</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2024</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,548</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,839</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (a.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.&#160;</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (&#8220;Offering Member&#8221;) to the other member(s) (&#8220;Non-Offering Member&#8221;) in which it either agrees to: (i)&#160;sell the entire ownership interest of the Offering Member to the Non-Offering Member (&#8220;Offer to Sell&#8221;) at a price as determined by the Offering Member (&#8220;Transfer Price&#8221;), or; (ii)&#160;purchase the entire ownership interest of the Non-Offering Member (&#8220;Offer to Purchase&#8221;) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i)&#160;purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii)&#160;sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.</p></div> <div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6) Recent Accounting Pronouncements</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, we adopted ASU No. 2016-15, <font style="font-style:italic;">Classification of Certain Cash Receipts and Cash Payments</font>, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows, and ASU 2016-18, <font style="font-style:italic;">Restricted Cash, </font>which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows.&nbsp;&nbsp;We adopted these ASUs by applying a retrospective transition method which requires a reclassification of our Consolidated Statement of Cash Flows for the period ending June 30, 2017. The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,732</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,109</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,253</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total Cash, Cash Equivalents and Restricted Cash</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,732</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,362</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02,<font style="font-style:italic;"> Leases</font> (&#8220;ASU 2016-02&#8221;), which introduces a lessee model that brings most leases on the balance sheet and, among other changes, eliminates the requirement in current Generally Accepted Accounting Principles in the United States of America &#8220;GAAP&#8221;) for an entity to use bright-line tests in determining lease classification. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, we adopted ASU 2014-09,&#160;<font style="font-style:italic;">Revenue From Contracts With Customers</font>&#160;(&#8220;ASU 2014-09&#8221;), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted the standard on January 1, 2018, using the modified retrospective approach, which requires a cumulative-effect adjustment to equity as of the date of adoption.&nbsp;&nbsp; ASU 2014-09 states that &#8220;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#8221; While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment.&nbsp;&nbsp;The adoption of this standard did not have a significant impact on our consolidated financial statements and no cumulative adjustment was recorded upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals) and bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.&nbsp;&nbsp;We apply FASB ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; with respect to tenant reimbursement and other property income, which totaled $2.8 million and $2.5 million for the three months ended June 30, 2018 and 2017, respectively, and $5.5 million and $4.9 million for the six months ended June 30, 2018 and 2017, respectively.&nbsp;&nbsp;The 2018 three and six month tenant reimbursement and other property income amounts also include a $1.7 million early lease termination fee recorded during the three months ended June 30, 2018. Tenant reimbursements for operating expenses are accrued as revenue and generally due monthly from tenants.&nbsp;&nbsp;Since payments with respect to tenant reimbursement income are generally due monthly, no contract assets or liabilities have been recognized.&nbsp;&nbsp;Revenue consisting of rental income from leasing arrangements are specifically excluded from FASB ASC Topic 606.</p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(7) Debt and Financial Instruments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Debt:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management routinely monitors and analyzes the Trust&#8217;s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $300 million revolving credit agreement, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances.&nbsp;&nbsp;This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust&#8217;s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust&#8217;s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust&#8217;s growth.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2018, we entered into a revolving credit agreement (&#8220;Credit Agreement&#8221;) which, among other things, increased our borrowing capacity by $50 million to $300 million and extended the maturity date from our previously existing facility. The replacement Credit Agreement, which is scheduled to mature in March, 2022, includes a $40 million sublimit for letters of credit and a $30 million sub limit for swingline/short-term loans.&nbsp;&nbsp;The Credit Agreement also provides for options to extend the maturity date for two additional six month periods. Additionally, the Credit Agreement includes an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement.&nbsp;&nbsp;Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust&#8217;s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines &#8220;Base Rate&#8221; as the greater of: (a)&#160;the administrative agent&#8217;s prime rate; (b)&#160;the federal funds effective rate plus 1/2 of 1%, and; (c)&#160;one month LIBOR plus 1%.&nbsp;&nbsp;A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.&nbsp;&nbsp;At June 30, 2018, the applicable margin over the LIBOR rate was 1.15%, the margin over the Base Rate was 0.15%, and the facility fee was 0.20%.&nbsp;&nbsp;</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 2018, we had $197.3 million of outstanding borrowings under our Credit Agreement and $102.7 million of available borrowing capacity.&nbsp;&nbsp;There are no compensating balance requirements.&nbsp;&nbsp;As disclosed below, during the first six months of 2018, we repaid an aggregate of $21.7 million on three mortgages utilizing borrowings under our Credit Agreement. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust&#8217;s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at June 30, 2018. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&gt; =$125,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,737</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.9</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 30%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36.2</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&gt; 1.50x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As indicated on the following table, we have eight mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of June 30, 2018 (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Facility Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<font style="font-family:Calibri;">&#160;</font>thousands) (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vibra Hospital-Corpus Christi fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,573</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.50</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July,&#160;2019</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,961</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,028</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,877</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January,&#160;2023</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2704 North Tenaya Way fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,940</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.95</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November, 2023</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III fixed</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,198</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April,&#160;2024</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,273</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2025</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children&#8217;s East Valley Care Center fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,307</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.95</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2030</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total, excluding net debt premium and net financing fees</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,157</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Less net financing fees</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(625</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Plus net debt premium</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total mortgages notes payable, non-recourse to us, net</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,806</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:2.22%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.44%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">(a)</p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 13, 2018, upon its maturity, a $4.1 million floating rate mortgage loan on the Sparks Medical Building/Vista Medical Terrace was fully repaid utilizing borrowings under our Credit Agreement.&nbsp;&nbsp; </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 5, 2018, upon its maturity, a $9.7 million floating rate mortgage loan on the Centennial Hills Medical Office Building was fully repaid utilizing borrowings under our Credit Agreement.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 2, 2018, upon its maturity, a $7.9 million fixed rate mortgage loan on the Rosenberg Children&#8217;s Medical Plaza was fully repaid utilizing borrowings under our Credit Agreement.&nbsp;&nbsp;</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mortgages are secured by the real property of the buildings as well as property leases and rents. The eight mortgages outstanding as of June 30, 2018 had a combined fair value of approximately $53.0 million. The fair value of our debt was computed based upon quotes received from financial institutions.&nbsp;&nbsp;We consider these to be &#8220;level 2&#8221; in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments.&nbsp;&nbsp;Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2017, we had eleven mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these eleven mortgages was $75.7 million and had a combined fair value of approximately $76.3 million.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financial Instruments:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2016, we entered into an interest rate cap on the total notional amount of $30 million whereby we paid a premium of $115,000.&nbsp;&nbsp;In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap.&nbsp;&nbsp;This interest rate cap became effective in January, 2017 and expires in March, 2019. From inception through June 30, 2018, we received or accrued approximately $39,000 in payments made to us by the counterparties (all received during the first six months of 2018) pursuant to the terms of these caps.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the third quarter of 2016, we entered into an additional interest rate cap agreement on a total notional amount of $30 million whereby we paid a premium of $55,000.&nbsp;&nbsp;In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.5% and one-month LIBOR if one-month LIBOR rises above 1.5% during the term of the cap.&nbsp;&nbsp;This interest rate cap became effective in October, 2016 and expires in March, 2019.&nbsp;&nbsp;From inception through June 30, 2018, we received or accrued approximately $39,000 in payments made to us by the counterparties (all received during the first six months of 2018) pursuant to the terms of these caps.</p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(8) Segment Reporting</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.&nbsp;&nbsp;No individual property meets the requirements necessary to be considered its own segment.</p></div> <div> <p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(9) Impact of Hurricane Harvey&nbsp;&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late August, 2017, five of our medical office buildings listed below located in the Houston, Texas area incurred extensive water damage as a result of Hurricane Harvey. Until various times during the second quarter of 2018, these properties were temporarily closed and non-operational as we continued to reconstruct and restore them to operational condition. As of June 30, 2018, reconstruction on all of the occupied space in these properties has been completed and operations have resumed. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2018, pursuant to the terms of a global settlement with our commercial property insurance carrier, we received $5.5 million of additional insurance recovery proceeds bringing the aggregate hurricane-related insurance recoveries to $12.5 million.&nbsp;&nbsp;The aggregate insurance proceeds recoveries, which are net of applicable deductibles, covered substantially all of the costs incurred related to the remediation, repair and reconstruction of each of these properties as well as business interruption recoveries for the lost income related to each of these properties during the period they were non-operational.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial results for the three months ended June 30, 2018 include approximately $194,000 of business interruption insurance recovery proceeds. Our financial results for the six months ended June 30, 2018 include approximately $1.2 million of business interruption insurance recovery proceeds, covering the period of late August, 2017 through June 30, 2018, approximately $500,000 of which relates to 2017. These business interruption insurance recovery proceeds are included in net cash provided by operating activities in our condensed consolidated statement of cash flows for the six-month period ended June 30, 2018. Additionally, the six months ended June 30, 2018 includes approximately $4.5 million of hurricane insurance recoveries in excess of property damage write-downs, which are included in net cash provided by investing activities in our condensed consolidated statement of cash flows for the six-month period ended June 30, 2018.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Our properties damaged and temporarily closed from Hurricane Harvey were:</font></p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cypresswood Professional Center &#8211;<font style="font-weight:normal;"> located in Spring, Texas and consisting of two MOBs. </font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Professional Buildings at King&#8217;s Crossing &#8211; <font style="font-weight:normal;">located in Kingwood, Texas and consisting of two MOBs. </font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kelsey-Seybold Clinic at King&#8217;s Crossing &#8211; <font style="font-weight:normal;">located in Kingwood, Texas and consisting of one MOB.</font></p></td></tr></table></div></div> <div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, we adopted ASU No. 2016-15, <font style="font-style:italic;">Classification of Certain Cash Receipts and Cash Payments</font>, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows, and ASU 2016-18, <font style="font-style:italic;">Restricted Cash, </font>which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows.&nbsp;&nbsp;We adopted these ASUs by applying a retrospective transition method which requires a reclassification of our Consolidated Statement of Cash Flows for the period ending June 30, 2017. The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,732</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,109</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,253</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total Cash, Cash Equivalents and Restricted Cash</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,732</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,362</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02,<font style="font-style:italic;"> Leases</font> (&#8220;ASU 2016-02&#8221;), which introduces a lessee model that brings most leases on the balance sheet and, among other changes, eliminates the requirement in current Generally Accepted Accounting Principles in the United States of America &#8220;GAAP&#8221;) for an entity to use bright-line tests in determining lease classification. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, we adopted ASU 2014-09,&#160;<font style="font-style:italic;">Revenue From Contracts With Customers</font>&#160;(&#8220;ASU 2014-09&#8221;), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted the standard on January 1, 2018, using the modified retrospective approach, which requires a cumulative-effect adjustment to equity as of the date of adoption.&nbsp;&nbsp; ASU 2014-09 states that &#8220;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#8221; While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment.&nbsp;&nbsp;The adoption of this standard did not have a significant impact on our consolidated financial statements and no cumulative adjustment was recorded upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals) and bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.&nbsp;&nbsp;We apply FASB ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; with respect to tenant reimbursement and other property income, which totaled $2.8 million and $2.5 million for the three months ended June 30, 2018 and 2017, respectively, and $5.5 million and $4.9 million for the six months ended June 30, 2018 and 2017, respectively.&nbsp;&nbsp;The 2018 three and six month tenant reimbursement and other property income amounts also include a $1.7 million early lease termination fee recorded during the three months ended June 30, 2018. Tenant reimbursements for operating expenses are accrued as revenue and generally due monthly from tenants.&nbsp;&nbsp;Since payments with respect to tenant reimbursement income are generally due monthly, no contract assets or liabilities have been recognized.&nbsp;&nbsp;Revenue consisting of rental income from leasing arrangements are specifically excluded from FASB ASC Topic 606.</p></div> <div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Hospital Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2026</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has one 5-year renewal option at the existing lease rate (through 2031).</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).</p></td></tr></table></div></div> <div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The following property table represents the four LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of June&#160;30, 2018:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC/LP</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (b.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (c.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</p></td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of June 30, 2018.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of June 30, 2018.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of June 30, 2018.&nbsp;&nbsp;This LP has a third-party term loan, which is non-recourse to us, of $5.1 million outstanding as of June&#160;30, 2018.</p></td></tr></table></div></div> <div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined statements of income (unaudited) for the LLCs/LPs accounted for under the equity method during the three and six months ended June 30, 2018 and 2017.&nbsp;&nbsp;The six months ended June 30, 2017 include the financial results of Arlington Medical Properties, LLC, through the March 13, 2017 divestiture date.&nbsp;&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.22%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.28%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.32%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,451</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,410</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,913</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,993</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">977</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">939</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,935</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,189</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">438</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">895</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,064</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">656</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">899</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">708</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,427</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,841</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">425</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">854</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,575</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our share of net income for the six months ended June 30, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC.&nbsp;&nbsp;This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.&nbsp;&nbsp; </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p></div> <div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs that were accounted for under the equity method as of June 30, 2018 and December 31, 2017:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including construction in progress</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,345</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,111</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,659</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,560</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,004</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,671</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,654</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,067</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,548</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,839</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,802</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,765</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,004</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,671</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in LLCs before amounts included in</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,655</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,671</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Amounts included in accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,011</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,895</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in LLCs, net</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,644</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,776</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div> <div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2018, and December&#160;31, 2017, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6/30/2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (5.00% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,134</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,202</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October, 2020</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (5.034% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,060</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,191</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (3.64% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,354</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,446</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2024</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,548</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,839</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (a.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.&#160;</p></td></tr></table></div></div> <div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.96%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,732</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,109</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,253</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.96%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total Cash, Cash Equivalents and Restricted Cash</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,732</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,362</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June&#160;30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&gt; =$125,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,737</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.9</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 30%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36.2</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&gt; 1.50x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div> <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Facility Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<font style="font-family:Calibri;">&#160;</font>thousands) (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vibra Hospital-Corpus Christi fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,573</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.50</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July,&#160;2019</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,961</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,028</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,877</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January,&#160;2023</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2704 North Tenaya Way fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,940</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.95</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November, 2023</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III fixed</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,198</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April,&#160;2024</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,273</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2025</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children&#8217;s East Valley Care Center fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,307</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.95</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2030</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total, excluding net debt premium and net financing fees</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,157</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Less net financing fees</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(625</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Plus net debt premium</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">274</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total mortgages notes payable, non-recourse to us, net</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,806</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:2.22%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.44%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">(a)</p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.</p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div> 0.33 0.95 4 P13Y P15Y 6 P5Y 3 0.20 0.22 0.21 0.23 17 0.28 0.32 0.30 0.32 P90D P180D P180D P5Y 2026-12 5485000 3030000 2648000 2026-12 2021-12 2021-12 P5Y P10Y P10Y 1 P5Y 2031 2 P5Y 2022 2031 P75Y 2 P10Y 13000000 0.0070 0.20 0.15 0 0 948000 874000 1900000 1700000 542000000 499000000 529000000 497000000 0.057 0.057 9200000 18300000 0.67 1.335 9000000 9200000 0.66 1.315 2018-07-03 2018-07-03 4000000 1.00 P9Y6M 2 P5Y 0 0 0.85 0.15 7900000 57300000 21400000 11300000 27200000 0.33 0.95 0.33 0.74 0.95 0.95 St. Matthews Medical Plaza II Mid Coast Hospital MOB Texoma Medical Plaza Forney Medical Plaza II 8400000 14100000 2100000 2500000 5100000 2451000 2410000 4913000 5993000 977000 939000 1935000 2189000 438000 421000 895000 1064000 328000 337000 656000 899000 708000 713000 1427000 1841000 284000 0 32345000 33111000 3659000 3560000 36004000 36671000 2654000 3067000 27548000 27839000 5802000 5765000 36004000 36671000 2011000 1895000 2644000 2776000 5134000 14060000 8354000 27548000 5202000 14191000 8446000 27839000 2020-10 2021-09 2024-12 0.0500 0.05034 0.0364 P60D P90D 4109000 11253000 5732000 15362000 0 2800000 2500000 5500000 4900000 0 0 1700000 300000000 300000000 50000000 2022-03 40000000 30000000 2 50000000 one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. 0.0110 0.01 0.0135 0.0010 0.0035 the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%. 0.0050 0.0015 0.0035 0.0115 0.0015 0.0020 102700000 21700000 3 125000000 0.60 0.30 0.60 0.0150 188737000 0.399 0.081 0.362 0.041 8 2573000 5961000 6028000 4877000 6940000 13198000 4273000 9307000 0.0650 0.0454 0.0427 0.0362 0.0495 0.0403 0.0556 0.0395 2019-07 2022-06 2022-12 2023-01 2023-11 2024-04 2025-06 2030-01 53157000 625000 274000 4100000 9700000 7900000 53000000 11 75700000 76300000 1 1 30000000 30000000 115000 55000 2019-03-31 2019-03-31 0.0150 0.015 39000 39000 1 5 5500000 12500000 1200000 194000 500000 4500000 2 2 1 Our share of net income for the six months ended June 30, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC. This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017. All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. UHS has one 5-year renewal option at the existing lease rate (through 2031). UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031). This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of June 30, 2018. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of June 30, 2018. We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of June 30, 2018. This LP has a third-party term loan, which is non-recourse to us, of $5.1 million outstanding as of June 30, 2018. All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity EX-101.SCH 7 uht-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Statements of Income link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statement of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - General link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Dividends link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Acquisitions and Dispositions link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Summarized Financial Information of Equity Affiliates link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Debt and Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Impact of Hurricane Harvey link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Recent Accounting Pronouncements (Policies) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Recent Accounting Pronouncements (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Debt and Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - General - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Dividends - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Acquisitions and Dispositions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Recent Accounting Pronouncements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Segment Reporting - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Impact of Hurricane Harvey - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 uht-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 uht-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 uht-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 uht-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2018
Jul. 31, 2018
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q2  
Trading Symbol UHT  
Entity Registrant Name UNIVERSAL HEALTH REALTY INCOME TRUST  
Entity Central Index Key 0000798783  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   13,745,138
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Revenues:        
Base rental - Non-related parties $ 10,217 $ 10,116 $ 20,544 $ 20,086
Bonus rental - UHS facilities 1,204 1,242 2,530 2,530
Revenues, Total 20,111 18,145 38,650 35,895
Expenses:        
Depreciation and amortization 6,111 6,295 12,398 12,440
Other operating expenses 5,445 4,923 10,653 9,628
Transaction costs   56   126
Costs and Expenses, Total 12,504 12,148 24,903 23,934
Income before equity in income of unconsolidated limited liability companies ("LLCs"), interest expense, hurricane insurance recovery proceeds and gain 7,607 5,997 13,747 11,961
Equity in income of unconsolidated LLCs [1] 425 498 854 1,575
Hurricane insurance recovery proceeds in excess of damaged property write-downs     4,535  
Hurricane business interruption insurance recovery proceeds 194   1,162  
Gain on Arlington transaction       27,196
Interest expense, net (2,421) (2,462) (4,889) (5,137)
Net income $ 5,805 $ 4,033 $ 15,409 $ 35,595
Basic earnings per share $ 0.42 $ 0.30 $ 1.12 $ 2.62
Diluted earnings per share $ 0.42 $ 0.30 $ 1.12 $ 2.62
Weighted average number of shares outstanding - Basic and Diluted 13,720 13,583 13,719 13,581
Management Service        
Expenses:        
Advisory fees to UHS $ 948 $ 874 $ 1,852 $ 1,740
UHS Facilities        
Revenues:        
Base rental - UHS facilities 4,187 4,303 8,363 8,383
UHS Facilities | Tenant Reimbursements And Other        
Revenues:        
Tenant reimbursements and other 303 245 598 464
Non-Related Parties | Tenant Reimbursements And Other        
Revenues:        
Tenant reimbursements and other $ 4,200 $ 2,239 $ 6,615 $ 4,432
[1] Our share of net income for the six months ended June 30, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC. This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Statement Of Income And Comprehensive Income [Abstract]        
Net income $ 5,805 $ 4,033 $ 15,409 $ 35,595
Other comprehensive income/(loss):        
Unrealized derivative gain/(loss) on interest rate caps 6 (75) 154 (93)
Total other comprehensive income/(loss): 6 (75) 154 (93)
Total comprehensive income $ 5,811 $ 3,958 $ 15,563 $ 35,502
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Real Estate Investments:    
Buildings and improvements and construction in progress $ 553,970 $ 546,634
Accumulated depreciation (163,434) (153,379)
Real Estate Investment Property, Net, Total 390,536 393,255
Land 53,396 53,142
Net Real Estate Investments 443,932 446,397
Investments in limited liability companies ("LLCs") 4,655 4,671
Other Assets:    
Cash and cash equivalents 5,732 3,387
Base and bonus rent and other receivables from UHS 2,610 2,680
Rent receivable - other 6,829 6,422
Intangible assets (net of accumulated amortization of $25.7 million and $28.7 million at June 30, 2018 and December 31, 2017, respectively) 19,253 20,559
Deferred charges and other assets, net 7,991 5,892
Total Assets 491,002 490,008
Liabilities:    
Line of credit borrowings 197,250 181,050
Mortgage notes payable, non-recourse to us, net 52,806 [1] 75,359
Accrued interest 504 540
Accrued expenses and other liabilities 12,193 12,188
Dividends payable 9,156  
Tenant reserves, deposits and deferred and prepaid rents 11,103 10,310
Total Liabilities 283,012 279,447
Equity:    
Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding
Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2018 - 13,744,229; 2017 - 13,735,369 137 137
Capital in excess of par value 265,544 265,335
Cumulative net income 633,529 618,120
Cumulative dividends (691,518) (673,175)
Accumulated other comprehensive income 298 144
Total Equity 207,990 210,561
Total Liabilities and Equity $ 491,002 $ 490,008
[1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Jun. 30, 2018
Dec. 31, 2017
Statement Of Financial Position [Abstract]    
Intangible assets, accumulated amortization $ 25.7 $ 28.7
Preferred shares of beneficial interest, par value $ 0.01 $ 0.01
Preferred shares of beneficial interest, shares authorized 5,000,000 5,000,000
Preferred shares of beneficial interest, issued 0 0
Preferred shares of beneficial interest, outstanding 0 0
Common shares, par value $ 0.01 $ 0.01
Common shares, shares authorized 95,000,000 95,000,000
Common shares, issued 13,744,229 13,735,369
Common shares, outstanding 13,744,229 13,735,369
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statement of Cash Flows - USD ($)
6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash flows from operating activities:    
Net income $ 15,409,000 $ 35,595,000
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 12,288,000 12,476,000
Amortization of debt premium (23,000) (100,000)
Stock-based compensation expense 254,000 252,000
Hurricane insurance recovery proceeds in excess of damaged property write-downs (4,535,000)  
Gain on Arlington transaction   (27,196,000)
Changes in assets and liabilities:    
Rent receivable (337,000) (683,000)
Accrued expenses and other liabilities (445,000) (398,000)
Tenant reserves, deposits and deferred and prepaid rents 713,000 79,000
Accrued interest (36,000) (62,000)
Leasing costs paid (597,000) (403,000)
Other, net 517,000 783,000
Net cash provided by operating activities 23,208,000 20,343,000
Cash flows from investing activities:    
Investments in LLCs (369,000) (532,000)
Repayments of advances made to LLC   216,000
Cash distributions in excess of income from LLCs 501,000 734,000
Additions to real estate investments, net (4,246,000) (6,537,000)
Cash proceeds received from divestiture of property, net of restricted cash 0 53,967,000
Restricted cash proceeds from divestiture of property   11,253,000
Hurricane insurance recovery proceeds in excess of damaged property write-downs 4,535,000  
Hurricane remediation payments (192,000)  
Deposits on real estate   (150,000)
Net cash paid for acquisition of property (4,053,000)  
Cash paid to acquire minority interests in majority-owned LLCs   (7,890,000)
Net cash (used in)/provided by investing activities (3,824,000) 51,061,000
Cash flows from financing activities:    
Net borrowings/(repayments) on line of credit 16,200,000 (18,650,000)
Repayments of mortgage notes payable (22,585,000) (36,473,000)
Proceeds from mortgage notes payable   13,200,000
Financing costs paid (1,527,000) (284,000)
Dividends paid (9,187,000) (17,887,000)
Issuance of shares of beneficial interest, net 60,000 122,000
Net cash used in financing activities (17,039,000) (59,972,000)
Increase in cash, cash equivalents and restricted cash 2,345,000 11,432,000
Cash, cash equivalents and restricted cash, beginning of period 3,387,000 3,930,000
Cash, cash equivalents and restricted cash, end of period 5,732,000 15,362,000
Supplemental disclosures of cash flow information:    
Interest paid $ 4,711,000 $ 5,039,000
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
General
6 Months Ended
Jun. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
General

(1) General

This Quarterly Report on Form 10-Q is for the quarter ended June 30, 2018. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.  As of June 30, 2018, we had investments in four jointly-owned LLCs/LPs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.

The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2017.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Certain prior period amounts on our statement of cash flows have been reclassified to conform to the current period presentation in connection with our adoption of ASU No. 2016-18, Restricted Cash.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions
6 Months Ended
Jun. 30, 2018
Related Party Transactions [Abstract]  
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each of the three hospital facilities leased to subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 20% and 22% of our consolidated revenues for the three months ended June 30, 2018 and 2017, respectively, and approximately 21% and 23% of our consolidated revenues for the six months ended June 30, 2018 and 2017, respectively. In addition, we have seventeen medical office buildings (“MOBs”), or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us, that include tenants which are subsidiaries of UHS.  The aggregate revenues generated from UHS-related tenants comprised approximately 28% and 32% of our consolidated revenues during the three-month periods ended June 30, 2018 and 2017, respectively, and approximately 30% and 32% of our consolidated revenues during the six-month periods ended June 30, 2018 and 2017, respectively.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month’s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.

In June, 2018, McAllen Medical Center, a wholly-owned subsidiary of UHS, provided notice to us, exercising the 5-year renewal option on their lease.  The renewal extended the lease term on this facility, at the existing lease rate, to December, 2026.

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2026

 

 

5

 

(a)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(b)

 

(a)

UHS has one 5-year renewal option at the existing lease rate (through 2031).

(b)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.  

In April, 2017, the recently constructed Henderson Medical Plaza MOB received its certificate of occupancy. Henderson Medical Plaza is located on the campus of the Henderson Hospital Medical Center, a newly constructed acute care hospital that is owned and operated by a subsidiary of UHS and was completed and opened during the fourth quarter of 2016.  A ground lease has been executed between the limited liability company that owns the MOB and a subsidiary of UHS, the terms of which include a seventy-five year lease term with two, ten-year renewal options at the lessee’s option at an adjusting lease rate. We have invested net cash of approximately $13.0 million on the development and construction of this MOB as of June 30, 2018.

Advisory Agreement:    UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the “Advisory Agreement”) dated December 24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. Our advisory fee is 0.70% of our average invested real estate assets, as derived from our consolidated balance sheet. In December of 2017, based upon a review of our advisory fee and other general and administrative expenses as compared to an industry peer group, the Advisory Agreement was renewed for 2018 pursuant to the same terms as the Advisory Agreement in place since 2013.

The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid at any time since our inception since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $948,000 and $874,000 for the three months ended June 30, 2018 and 2017, respectively, and were based upon average invested real estate assets of $542 million and $499 million for the three-month periods ended June 30, 2018 and 2017, respectively.  Advisory fees incurred and paid (or payable) to UHS amounted to $1.9 million and $1.7 million for the six months ended June 30, 2018 and 2017, respectively, and were based upon average invested real estate assets of $529 million and $497 million for the six-month periods ended June 30, 2018 and 2017, respectively

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of June 30, 2018 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

Share Ownership: At each of June 30, 2018 and December 31, 2017, UHS owned 5.7%, of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 28% and 32% of our consolidated revenues during the three-month periods ended June 30, 2018 and 2017, respectively, and 30% and 32% of our consolidated revenues during the six-month periods ended June 30, 2018 and 2017, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Dividends
6 Months Ended
Jun. 30, 2018
Equity [Abstract]  
Dividends

(3) Dividends

Dividends:

We declared dividends of $9.2 million, or $.67 per share, during the second quarter of 2018, which were paid on July 3, 2018.  We declared and paid dividends of $9.0 million, or $.66 per share, during the second quarter of 2017. During the six-month period ended June 30, 2018, we declared dividends of $18.3 million, or $1.335 per share, $9.2 million of which was paid on July 3, 2018. We declared and paid dividends of $17.9 million, or $1.315 per share, during the six-month period ended June 30, 2017.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions and Dispositions
6 Months Ended
Jun. 30, 2018
Business Combinations [Abstract]  
Acquisitions and Dispositions

(4) Acquisitions and Dispositions

Six Months Ended June 30, 2018:

Acquisitions:

In June, 2018, we acquired the Beaumont Medical Sleep Center Building located in Southfield, Michigan for a purchase price of approximately $4.0 million.  This building is 100% leased under the terms of a triple net lease with a remaining initial lease term of approximately 9.5 years at the time of purchase, with two, five year renewal options.

Dispositions:

There were no dispositions during the first six months of 2018.

Six Months Ended June 30, 2017:

Acquisitions:

 There were no acquisitions during the first six months of 2017.

Disposition:

During March, 2017, Arlington Medical Properties, LLC, a formerly jointly-owned limited liability company in which we held an 85% noncontrolling ownership interest, sold the real estate assets of St. Mary’s Professional Office Building (“St. Mary’s”) as part of a series of planned tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.  St. Mary’s is a multi-tenant medical office building located in Reno, Nevada.  A third party member owned the remaining 15% of Arlington Medical Properties LLC, which we acquired prior to the divestiture of St. Mary’s for a purchase price of $7.9 million. The divestiture of St. Mary’s generated an aggregate of approximately $57.3 million of net cash proceeds to us (approximately $11.3 million of which was held as restricted cash by a qualified 1031 exchange intermediary until the third quarter of 2017).  These proceeds, which were net of closing costs and the purchase price paid for the minority member’s ownership interest in the LLC, include repayment to us of a $21.4 million member loan.  Our results of operations for the six-month period ended June 30, 2017 included a net gain of $27.2 million (net of related transaction costs) recorded in connection with this transaction.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summarized Financial Information of Equity Affiliates
6 Months Ended
Jun. 30, 2018
Equity Method Investments And Joint Ventures [Abstract]  
Summarized Financial Information of Equity Affiliates

(5) Summarized Financial Information of Equity Affiliates

In accordance with the Financial Accounting Standards Board’s (“FASB”) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

In the Condensed Consolidated Statements of Cash Flows, distributions and equity in net income are presented net as cash flows from operating activities. Cumulative distributions received exceeding cumulative equity in earnings represent returns of investments and are classified as cash flows from investing activities in the Condensed Consolidated Statements of Cash Flows.

At June 30, 2018, we have non-controlling equity investments or commitments in four jointly-owned LLCs/LPs which own MOBs. As of June 30, 2018, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties.

 The following property table represents the four LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of June 30, 2018:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

 

(a.)

This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of June 30, 2018.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of June 30, 2018.

(c.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of June 30, 2018.  This LP has a third-party term loan, which is non-recourse to us, of $5.1 million outstanding as of June 30, 2018.

Below are the condensed combined statements of income (unaudited) for the LLCs/LPs accounted for under the equity method during the three and six months ended June 30, 2018 and 2017.  The six months ended June 30, 2017 include the financial results of Arlington Medical Properties, LLC, through the March 13, 2017 divestiture date.  

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

 

 

 

(amounts in thousands)

(amounts in thousands)

Revenues

 

$

2,451

 

 

$

2,410

 

 

$

4,913

 

 

$

5,993

 

 

Operating expenses

 

 

977

 

 

 

939

 

 

 

1,935

 

 

 

2,189

 

 

Depreciation and amortization

 

 

438

 

 

 

421

 

 

 

895

 

 

 

1,064

 

 

Interest, net

 

 

328

 

 

 

337

 

 

 

656

 

 

 

899

 

 

Net income

 

$

708

 

 

$

713

 

 

$

1,427

 

 

$

1,841

 

 

Our share of net income (a.)

 

$

425

 

 

$

498

 

 

$

854

 

 

$

1,575

 

 

 

(a.)

Our share of net income for the six months ended June 30, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC.  This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.  

 

Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs that were accounted for under the equity method as of June 30, 2018 and December 31, 2017:

 

 

 

June 30,

2018

 

 

December 31,

2017

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

32,345

 

 

$

33,111

 

Other assets

 

 

3,659

 

 

 

3,560

 

Total assets

 

$

36,004

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Other liabilities

 

$

2,654

 

 

$

3,067

 

Mortgage notes payable, non-recourse to us

 

 

27,548

 

 

 

27,839

 

Equity

 

 

5,802

 

 

 

5,765

 

Total liabilities and equity

 

$

36,004

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Investments in LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

4,655

 

 

$

4,671

 

   Amounts included in accrued expenses and other liabilities

 

 

(2,011

)

 

 

(1,895

)

Our share of equity in LLCs, net

 

$

2,644

 

 

$

2,776

 

   

As of June 30, 2018, and December 31, 2017, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

6/30/2018

 

 

12/31/2017

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan)

 

$

5,134

 

 

$

5,202

 

 

October, 2020

Grayson Properties (5.034% fixed rate mortgage loan)

 

 

14,060

 

 

 

14,191

 

 

September, 2021

Brunswick Associates (3.64% fixed rate mortgage loan)

 

 

8,354

 

 

 

8,446

 

 

December, 2024

 

 

$

27,548

 

 

$

27,839

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

Pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Recent Accounting Pronouncements
6 Months Ended
Jun. 30, 2018
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]  
Recent Accounting Pronouncements

(6) Recent Accounting Pronouncements

On January 1, 2018, we adopted ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows, and ASU 2016-18, Restricted Cash, which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows.  We adopted these ASUs by applying a retrospective transition method which requires a reclassification of our Consolidated Statement of Cash Flows for the period ending June 30, 2017. The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:

 

 

 

 

(In thousands)

 

June 30, 2018

 

 

June 30, 2017

 

Cash and cash equivalents

 

$

5,732

 

 

$

4,109

 

Restricted cash

 

 

-

 

 

 

11,253

 

Total Cash, Cash Equivalents and Restricted Cash

 

$

5,732

 

 

$

15,362

 

 

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which introduces a lessee model that brings most leases on the balance sheet and, among other changes, eliminates the requirement in current Generally Accepted Accounting Principles in the United States of America “GAAP”) for an entity to use bright-line tests in determining lease classification. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements.

 

On January 1, 2018, we adopted ASU 2014-09, Revenue From Contracts With Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted the standard on January 1, 2018, using the modified retrospective approach, which requires a cumulative-effect adjustment to equity as of the date of adoption.   ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment.  The adoption of this standard did not have a significant impact on our consolidated financial statements and no cumulative adjustment was recorded upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.

 

Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals) and bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.  We apply FASB ASC Topic 606, “Revenue from Contracts with Customers” with respect to tenant reimbursement and other property income, which totaled $2.8 million and $2.5 million for the three months ended June 30, 2018 and 2017, respectively, and $5.5 million and $4.9 million for the six months ended June 30, 2018 and 2017, respectively.  The 2018 three and six month tenant reimbursement and other property income amounts also include a $1.7 million early lease termination fee recorded during the three months ended June 30, 2018. Tenant reimbursements for operating expenses are accrued as revenue and generally due monthly from tenants.  Since payments with respect to tenant reimbursement income are generally due monthly, no contract assets or liabilities have been recognized.  Revenue consisting of rental income from leasing arrangements are specifically excluded from FASB ASC Topic 606.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt and Financial Instruments
6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Debt and Financial Instruments

(7) Debt and Financial Instruments

Debt:

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $300 million revolving credit agreement, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On March 27, 2018, we entered into a revolving credit agreement (“Credit Agreement”) which, among other things, increased our borrowing capacity by $50 million to $300 million and extended the maturity date from our previously existing facility. The replacement Credit Agreement, which is scheduled to mature in March, 2022, includes a $40 million sublimit for letters of credit and a $30 million sub limit for swingline/short-term loans.  The Credit Agreement also provides for options to extend the maturity date for two additional six month periods. Additionally, the Credit Agreement includes an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement.  Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines “Base Rate” as the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At June 30, 2018, the applicable margin over the LIBOR rate was 1.15%, the margin over the Base Rate was 0.15%, and the facility fee was 0.20%.  

At June 30, 2018, we had $197.3 million of outstanding borrowings under our Credit Agreement and $102.7 million of available borrowing capacity.  There are no compensating balance requirements.  As disclosed below, during the first six months of 2018, we repaid an aggregate of $21.7 million on three mortgages utilizing borrowings under our Credit Agreement.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at June 30, 2018. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

June 30,

2018

 

Tangible net worth

 

> =$125,000

 

$

188,737

 

Total leverage

 

< 60%

 

 

39.9

%

Secured leverage

 

< 30%

 

 

8.1

%

Unencumbered leverage

 

< 60%

 

 

36.2

%

Fixed charge coverage

 

> 1.50x

 

4.1x

 

 

As indicated on the following table, we have eight mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of June 30, 2018 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

$

2,573

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

5,961

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,028

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,877

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,940

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

13,198

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

4,273

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

9,307

 

 

 

3.95

%

 

January, 2030

Total, excluding net debt premium and net financing fees

 

 

53,157

 

 

 

 

 

 

 

     Less net financing fees

 

 

(625

)

 

 

 

 

 

 

     Plus net debt premium

 

 

274

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

52,806

 

 

 

 

 

 

 

 

 

(a)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

 

On February 13, 2018, upon its maturity, a $4.1 million floating rate mortgage loan on the Sparks Medical Building/Vista Medical Terrace was fully repaid utilizing borrowings under our Credit Agreement.  

On April 5, 2018, upon its maturity, a $9.7 million floating rate mortgage loan on the Centennial Hills Medical Office Building was fully repaid utilizing borrowings under our Credit Agreement.

On May 2, 2018, upon its maturity, a $7.9 million fixed rate mortgage loan on the Rosenberg Children’s Medical Plaza was fully repaid utilizing borrowings under our Credit Agreement.  

The mortgages are secured by the real property of the buildings as well as property leases and rents. The eight mortgages outstanding as of June 30, 2018 had a combined fair value of approximately $53.0 million. The fair value of our debt was computed based upon quotes received from financial institutions.  We consider these to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments.  Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

At December 31, 2017, we had eleven mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these eleven mortgages was $75.7 million and had a combined fair value of approximately $76.3 million.

Financial Instruments:

During the second quarter of 2016, we entered into an interest rate cap on the total notional amount of $30 million whereby we paid a premium of $115,000.  In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap.  This interest rate cap became effective in January, 2017 and expires in March, 2019. From inception through June 30, 2018, we received or accrued approximately $39,000 in payments made to us by the counterparties (all received during the first six months of 2018) pursuant to the terms of these caps.

During the third quarter of 2016, we entered into an additional interest rate cap agreement on a total notional amount of $30 million whereby we paid a premium of $55,000.  In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.5% and one-month LIBOR if one-month LIBOR rises above 1.5% during the term of the cap.  This interest rate cap became effective in October, 2016 and expires in March, 2019.  From inception through June 30, 2018, we received or accrued approximately $39,000 in payments made to us by the counterparties (all received during the first six months of 2018) pursuant to the terms of these caps.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting
6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Segment Reporting

(8) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  No individual property meets the requirements necessary to be considered its own segment.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Impact of Hurricane Harvey
6 Months Ended
Jun. 30, 2018
Extraordinary And Unusual Items [Abstract]  
Impact of Hurricane Harvey

(9) Impact of Hurricane Harvey  

In late August, 2017, five of our medical office buildings listed below located in the Houston, Texas area incurred extensive water damage as a result of Hurricane Harvey. Until various times during the second quarter of 2018, these properties were temporarily closed and non-operational as we continued to reconstruct and restore them to operational condition. As of June 30, 2018, reconstruction on all of the occupied space in these properties has been completed and operations have resumed.

 

During 2018, pursuant to the terms of a global settlement with our commercial property insurance carrier, we received $5.5 million of additional insurance recovery proceeds bringing the aggregate hurricane-related insurance recoveries to $12.5 million.  The aggregate insurance proceeds recoveries, which are net of applicable deductibles, covered substantially all of the costs incurred related to the remediation, repair and reconstruction of each of these properties as well as business interruption recoveries for the lost income related to each of these properties during the period they were non-operational.

 

Our financial results for the three months ended June 30, 2018 include approximately $194,000 of business interruption insurance recovery proceeds. Our financial results for the six months ended June 30, 2018 include approximately $1.2 million of business interruption insurance recovery proceeds, covering the period of late August, 2017 through June 30, 2018, approximately $500,000 of which relates to 2017. These business interruption insurance recovery proceeds are included in net cash provided by operating activities in our condensed consolidated statement of cash flows for the six-month period ended June 30, 2018. Additionally, the six months ended June 30, 2018 includes approximately $4.5 million of hurricane insurance recoveries in excess of property damage write-downs, which are included in net cash provided by investing activities in our condensed consolidated statement of cash flows for the six-month period ended June 30, 2018.

 

Our properties damaged and temporarily closed from Hurricane Harvey were:

 

Cypresswood Professional Center – located in Spring, Texas and consisting of two MOBs.

 

Professional Buildings at King’s Crossing – located in Kingwood, Texas and consisting of two MOBs.

 

Kelsey-Seybold Clinic at King’s Crossing – located in Kingwood, Texas and consisting of one MOB.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Recent Accounting Pronouncements (Policies)
6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Recent Accounting Pronouncements

On January 1, 2018, we adopted ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows, and ASU 2016-18, Restricted Cash, which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows.  We adopted these ASUs by applying a retrospective transition method which requires a reclassification of our Consolidated Statement of Cash Flows for the period ending June 30, 2017. The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:

 

 

 

 

(In thousands)

 

June 30, 2018

 

 

June 30, 2017

 

Cash and cash equivalents

 

$

5,732

 

 

$

4,109

 

Restricted cash

 

 

-

 

 

 

11,253

 

Total Cash, Cash Equivalents and Restricted Cash

 

$

5,732

 

 

$

15,362

 

 

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which introduces a lessee model that brings most leases on the balance sheet and, among other changes, eliminates the requirement in current Generally Accepted Accounting Principles in the United States of America “GAAP”) for an entity to use bright-line tests in determining lease classification. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements.

 

On January 1, 2018, we adopted ASU 2014-09, Revenue From Contracts With Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted the standard on January 1, 2018, using the modified retrospective approach, which requires a cumulative-effect adjustment to equity as of the date of adoption.   ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment.  The adoption of this standard did not have a significant impact on our consolidated financial statements and no cumulative adjustment was recorded upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.

 

Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals) and bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.  We apply FASB ASC Topic 606, “Revenue from Contracts with Customers” with respect to tenant reimbursement and other property income, which totaled $2.8 million and $2.5 million for the three months ended June 30, 2018 and 2017, respectively, and $5.5 million and $4.9 million for the six months ended June 30, 2018 and 2017, respectively.  The 2018 three and six month tenant reimbursement and other property income amounts also include a $1.7 million early lease termination fee recorded during the three months ended June 30, 2018. Tenant reimbursements for operating expenses are accrued as revenue and generally due monthly from tenants.  Since payments with respect to tenant reimbursement income are generally due monthly, no contract assets or liabilities have been recognized.  Revenue consisting of rental income from leasing arrangements are specifically excluded from FASB ASC Topic 606.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables)
6 Months Ended
Jun. 30, 2018
Related Party Transactions [Abstract]  
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2026

 

 

5

 

(a)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(b)

 

(a)

UHS has one 5-year renewal option at the existing lease rate (through 2031).

(b)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summarized Financial Information of Equity Affiliates (Tables)
6 Months Ended
Jun. 30, 2018
Equity Method Investments And Joint Ventures [Abstract]  
Limited Liability Companies Accounted for Under Equity Method

 The following property table represents the four LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of June 30, 2018:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

 

(a.)

This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of June 30, 2018.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of June 30, 2018.

(c.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of June 30, 2018.  This LP has a third-party term loan, which is non-recourse to us, of $5.1 million outstanding as of June 30, 2018.

Condensed Combined Statements of Income (Unaudited) for Limited Liability Companies Accounted for Under Equity Method

Below are the condensed combined statements of income (unaudited) for the LLCs/LPs accounted for under the equity method during the three and six months ended June 30, 2018 and 2017.  The six months ended June 30, 2017 include the financial results of Arlington Medical Properties, LLC, through the March 13, 2017 divestiture date.  

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

 

 

 

(amounts in thousands)

(amounts in thousands)

Revenues

 

$

2,451

 

 

$

2,410

 

 

$

4,913

 

 

$

5,993

 

 

Operating expenses

 

 

977

 

 

 

939

 

 

 

1,935

 

 

 

2,189

 

 

Depreciation and amortization

 

 

438

 

 

 

421

 

 

 

895

 

 

 

1,064

 

 

Interest, net

 

 

328

 

 

 

337

 

 

 

656

 

 

 

899

 

 

Net income

 

$

708

 

 

$

713

 

 

$

1,427

 

 

$

1,841

 

 

Our share of net income (a.)

 

$

425

 

 

$

498

 

 

$

854

 

 

$

1,575

 

 

 

(a.)

Our share of net income for the six months ended June 30, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC.  This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.  

 

Condensed Combined Balance Sheets (Unaudited) for LLCs Accounted for Under Equity Method

Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs that were accounted for under the equity method as of June 30, 2018 and December 31, 2017:

 

 

 

June 30,

2018

 

 

December 31,

2017

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

32,345

 

 

$

33,111

 

Other assets

 

 

3,659

 

 

 

3,560

 

Total assets

 

$

36,004

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Other liabilities

 

$

2,654

 

 

$

3,067

 

Mortgage notes payable, non-recourse to us

 

 

27,548

 

 

 

27,839

 

Equity

 

 

5,802

 

 

 

5,765

 

Total liabilities and equity

 

$

36,004

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Investments in LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

4,655

 

 

$

4,671

 

   Amounts included in accrued expenses and other liabilities

 

 

(2,011

)

 

 

(1,895

)

Our share of equity in LLCs, net

 

$

2,644

 

 

$

2,776

 

 

Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's Accounted Under Equity Method

As of June 30, 2018, and December 31, 2017, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

6/30/2018

 

 

12/31/2017

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan)

 

$

5,134

 

 

$

5,202

 

 

October, 2020

Grayson Properties (5.034% fixed rate mortgage loan)

 

 

14,060

 

 

 

14,191

 

 

September, 2021

Brunswick Associates (3.64% fixed rate mortgage loan)

 

 

8,354

 

 

 

8,446

 

 

December, 2024

 

 

$

27,548

 

 

$

27,839

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Recent Accounting Pronouncements (Tables)
6 Months Ended
Jun. 30, 2018
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]  
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:

 

 

 

 

(In thousands)

 

June 30, 2018

 

 

June 30, 2017

 

Cash and cash equivalents

 

$

5,732

 

 

$

4,109

 

Restricted cash

 

 

-

 

 

 

11,253

 

Total Cash, Cash Equivalents and Restricted Cash

 

$

5,732

 

 

$

15,362

 

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt and Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

June 30,

2018

 

Tangible net worth

 

> =$125,000

 

$

188,737

 

Total leverage

 

< 60%

 

 

39.9

%

Secured leverage

 

< 30%

 

 

8.1

%

Unencumbered leverage

 

< 60%

 

 

36.2

%

Fixed charge coverage

 

> 1.50x

 

4.1x

 

 

Outstanding Mortgages, Excluding Net Debt Premium

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

$

2,573

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

5,961

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,028

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,877

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,940

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

13,198

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

4,273

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

9,307

 

 

 

3.95

%

 

January, 2030

Total, excluding net debt premium and net financing fees

 

 

53,157

 

 

 

 

 

 

 

     Less net financing fees

 

 

(625

)

 

 

 

 

 

 

     Plus net debt premium

 

 

274

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

52,806

 

 

 

 

 

 

 

 

 

(a)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

 

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
General - Additional Information (Detail)
Jun. 30, 2018
Property
4 Unconsolidated Limited Liability Companies / Limited Partner | Minimum  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Non-controlling equity interest, ownership percentage 33.00%
4 Unconsolidated Limited Liability Companies / Limited Partner | Maximum  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Non-controlling equity interest, ownership percentage 95.00%
Medical office buildings | Limited Liability Companies  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Number of real estate investments 4
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2018
USD ($)
Property
Time
Apr. 30, 2017
Time
Jun. 30, 2018
USD ($)
Property
Time
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Property
Time
Jun. 30, 2017
USD ($)
Dec. 31, 2017
Related Party Transaction [Line Items]              
Annual advisory fee as percentage of average invested real estate assets 0.70%   0.70%   0.70%    
Management Service              
Related Party Transaction [Line Items]              
Advisory fee     $ 948,000 $ 874,000 $ 1,852,000 $ 1,740,000  
Universal Health Services, Inc              
Related Party Transaction [Line Items]              
Number of term renewal options | Time 6   6   6    
Additional renewal terms         5 years    
Number of medical office buildings and free standing emergency departments | Property         17    
Option to renew lease, notice period prior to termination date of current term         90 days    
Period to purchase respective leased facilities at same price after lease terms         180 days    
Renewal period of respective leased facilities at same price after lease terms         180 days    
Percentage ownership of outstanding shares 5.70%   5.70%   5.70%   5.70%
Universal Health Services, Inc | Henderson Medical Plaza              
Related Party Transaction [Line Items]              
Number of term renewal options | Time   2          
Additional renewal terms   10 years          
Ground lease agreement period   75 years          
Amount invested in MOB under construction $ 13,000,000   $ 13,000,000   $ 13,000,000    
Universal Health Services, Inc | McAllen Medical Center              
Related Party Transaction [Line Items]              
Renewal options term at existing lease rates 5 years       5 years    
Extended lease terms at existing lease rates 2026-12       2026-12    
Number of renewal options at existing lease rates | Time         1    
Universal Health Services, Inc | Customer Concentration Risk | Revenues              
Related Party Transaction [Line Items]              
Percentage of revenues generated from leases and tenants     20.00% 22.00% 21.00% 23.00%  
Universal Health Services, Inc | Customer Concentration Risk | Revenues | Tenants              
Related Party Transaction [Line Items]              
Percentage of revenues generated from leases and tenants     28.00% 32.00% 30.00% 32.00%  
Universal Health Services, Inc | Hospital Facilities Leased              
Related Party Transaction [Line Items]              
Number of hospital facilities leased | Property 3   3   3    
Universal Health Services, Inc | Minimum              
Related Party Transaction [Line Items]              
Initial lease terms         13 years    
Universal Health Services, Inc | Maximum              
Related Party Transaction [Line Items]              
Initial lease terms         15 years    
Universal Health Services of Delaware Inc              
Related Party Transaction [Line Items]              
Annual incentive fee to Advisor as percentage of cash available for distribution 20.00%   20.00%   20.00%    
Incentive fees         $ 0 $ 0  
Average invested real estate assets     $ 542,000,000 $ 499,000,000 529,000,000 497,000,000  
Universal Health Services of Delaware Inc | Management Service              
Related Party Transaction [Line Items]              
Advisory fee     $ 948,000 $ 874,000 $ 1,900,000 $ 1,700,000  
Universal Health Services of Delaware Inc | Minimum              
Related Party Transaction [Line Items]              
Percentage of equity to be exceeded for incentive distribution 15.00%   15.00%   15.00%    
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) - Universal Health Services, Inc
1 Months Ended 6 Months Ended
Jun. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
McAllen Medical Center    
Operating Leased Assets [Line Items]    
Annual Minimum Rent $ 5,485,000 $ 5,485,000
End of Lease Term 2026-12 2026-12
Renewal Term (years) 5 years [1] 5 years [1]
Wellington Regional Medical Center    
Operating Leased Assets [Line Items]    
Annual Minimum Rent $ 3,030,000 $ 3,030,000
End of Lease Term   2021-12
Renewal Term (years) 10 years [2] 10 years [2]
Southwest Healthcare System, Inland Valley Campus    
Operating Leased Assets [Line Items]    
Annual Minimum Rent $ 2,648,000 $ 2,648,000
End of Lease Term   2021-12
Renewal Term (years) 10 years [2] 10 years [2]
[1] UHS has one 5-year renewal option at the existing lease rate (through 2031).
[2] UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) - Universal Health Services, Inc
1 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2018
Time
RenewalOption
McAllen Medical Center    
Operating Leased Assets [Line Items]    
Number of renewal options at existing lease rates | Time   1
Renewal options term at existing lease rates 5 years 5 years
Renewal options at existing lease rates expiration year   2031
Wellington Regional Medical Center And Southwest Healthcare System    
Operating Leased Assets [Line Items]    
Number of renewal options at fair market value lease rates | RenewalOption   2
Renewal options term at fair market value lease rates   5 years
Wellington Regional Medical Center And Southwest Healthcare System | Maximum    
Operating Leased Assets [Line Items]    
Renewal options at fair market value lease rates expiration year   2031
Wellington Regional Medical Center And Southwest Healthcare System | Minimum    
Operating Leased Assets [Line Items]    
Renewal options at fair market value lease rates expiration year   2022
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Dividends - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jul. 03, 2018
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dividends and Equity Issuance [Line Items]          
Dividends declared   $ 9,200   $ 18,300  
Declared dividends, per share   $ 0.67   $ 1.335  
Dividends declared and paid     $ 9,000 $ 9,187 $ 17,887
Declared and paid dividends, per share     $ 0.66   $ 1.315
Dividends payable, date to be paid   Jul. 03, 2018   Jul. 03, 2018  
Subsequent Event          
Dividends and Equity Issuance [Line Items]          
Dividends declared and paid $ 9,200        
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions and Dispositions - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Mar. 31, 2017
USD ($)
Mar. 31, 2017
USD ($)
Jun. 30, 2018
USD ($)
Time
Jun. 30, 2017
USD ($)
Acquisition
Sep. 30, 2017
USD ($)
Mar. 12, 2017
Business Acquisitions And Dispositions [Line Items]            
Cash received from dispositions     $ 0 $ 53,967,000    
Number of acquisitions | Acquisition       0    
Repayment of loan   $ 21,400,000        
St. Mary's Professional Office Building            
Business Acquisitions And Dispositions [Line Items]            
Net cash proceeds received from divestiture $ 57,300,000 $ 57,300,000        
Net sale proceeds due         $ 11,300,000  
Gain on divestiture of property       $ 27,200,000    
Arlington Medical Properties            
Business Acquisitions And Dispositions [Line Items]            
Total purchase price $ 7,900,000          
Ownership prior to minority interest purchase 85.00% 85.00%        
Remaining percentage owned by third party member           15.00%
Beaumont Medical Sleep Center Building            
Business Acquisitions And Dispositions [Line Items]            
Total purchase price     $ 4,000,000      
Percentage of building area leased     100.00%      
Initial lease terms     9 years 6 months      
Number of term renewal options | Time     2      
Additional renewal terms     5 years      
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summarized Financial Information of Equity Affiliates - Additional Information (Detail)
6 Months Ended
Jun. 30, 2018
Property
Limited Liability Companies | Medical office buildings  
Schedule Of Equity Method Investments [Line Items]  
Number of real estate investments 4
Minimum  
Schedule Of Equity Method Investments [Line Items]  
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member 60 days
Maximum  
Schedule Of Equity Method Investments [Line Items]  
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member 90 days
4 Unconsolidated Limited Liability Companies / Limited Partner | Minimum  
Schedule Of Equity Method Investments [Line Items]  
Non-controlling equity interest, ownership percentage 33.00%
4 Unconsolidated Limited Liability Companies / Limited Partner | Maximum  
Schedule Of Equity Method Investments [Line Items]  
Non-controlling equity interest, ownership percentage 95.00%
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Limited Liability Companies Accounted for Under Equity Method (Detail) - Equity Method Investments
6 Months Ended
Jun. 30, 2018
Suburban Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 33.00%
Property Owned by LLC/LP St. Matthews Medical Plaza II
Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Ownership 74.00% [1]
Property Owned by LLC/LP Mid Coast Hospital MOB [1]
Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [2]
Property Owned by LLC/LP Texoma Medical Plaza [2]
FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [3]
Property Owned by LLC/LP Forney Medical Plaza II [3]
[1] This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of June 30, 2018.
[2] This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of June 30, 2018.
[3] We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of June 30, 2018. This LP has a third-party term loan, which is non-recourse to us, of $5.1 million outstanding as of June 30, 2018.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail)
$ in Millions
Jun. 30, 2018
USD ($)
Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan $ 8.4
Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan 14.1
FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan 5.1
Committed investment in equity and debt financing, funded 2.1
Commitment to investment $ 2.5
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Equity Method Investments And Joint Ventures [Abstract]        
Revenues $ 2,451 $ 2,410 $ 4,913 $ 5,993
Operating expenses 977 939 1,935 2,189
Depreciation and amortization 438 421 895 1,064
Interest, net 328 337 656 899
Net income 708 713 1,427 1,841
Our share of net income [1] $ 425 $ 498 $ 854 $ 1,575
[1] Our share of net income for the six months ended June 30, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC. This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) - USD ($)
6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Arlington Medical Properties    
Schedule Of Equity Method Investments [Line Items]    
Interest income earned on various advances made to LLCs $ 0 $ 284,000
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Equity Method Investments And Joint Ventures [Abstract]    
Net property, including construction in progress $ 32,345 $ 33,111
Other assets 3,659 3,560
Total assets 36,004 36,671
Other liabilities 2,654 3,067
Mortgage notes payable, non-recourse to us 27,548 27,839
Equity 5,802 5,765
Total liabilities and equity 36,004 36,671
Investments in LLCs before amounts included in accrued expenses and other liabilities 4,655 4,671
Amounts included in accrued expenses and other liabilities (2,011) (1,895)
Our share of equity in LLCs, net $ 2,644 $ 2,776
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance $ 27,548 $ 27,839
Equity Method Investments    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] 27,548 27,839
Equity Method Investments | FTX MOB Phase II    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 5,134 5,202
Maturity Date 2020-10  
Equity Method Investments | Grayson Properties    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 14,060 14,191
Maturity Date 2021-09  
Equity Method Investments | Brunswick Associates    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 8,354 $ 8,446
Maturity Date 2024-12  
[1] All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Parenthetical) (Detail)
Jun. 30, 2018
5.00% Fixed Rate Mortgage Loan | FTX MOB Phase II  
Schedule Of Equity Method Investments [Line Items]  
Loan interest rate fixed percentage 5.00%
5.034% Fixed Rate Mortgage Loan | Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Loan interest rate fixed percentage 5.034%
3.64% Fixed Rate Mortgage Loan | Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Loan interest rate fixed percentage 3.64%
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
Jun. 30, 2017
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]      
Cash and cash equivalents $ 5,732 $ 3,387 $ 4,109
Restricted cash     11,253
Total Cash, Cash Equivalents and Restricted Cash $ 5,732   $ 15,362
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Recent Accounting Pronouncements - Additional Information (Detail) - Topic 606 - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]        
Cumulative adjustment $ 0   $ 0  
Contract assets 0   0  
Contract liabilities 0   0  
Lease termination fee 1,700,000      
Tenant Reimbursement and Other Property Income        
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]        
Revenue from contracts with customers $ 2,800,000 $ 2,500,000 $ 5,500,000 $ 4,900,000
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt and Financial Instruments - Additional Information (Detail)
3 Months Ended 6 Months Ended 24 Months Ended 27 Months Ended
May 02, 2018
USD ($)
Apr. 05, 2018
USD ($)
Mar. 27, 2018
USD ($)
Option
Feb. 13, 2018
USD ($)
Sep. 30, 2016
USD ($)
Derivative
Jun. 30, 2016
USD ($)
Derivative
Jun. 30, 2018
USD ($)
MortgageLoan
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
MortgageLoan
Jun. 30, 2018
USD ($)
MortgageLoan
Dec. 31, 2017
USD ($)
MortgageLoan
Debt Instrument [Line Items]                      
Outstanding borrowings under revolving credit agreement             $ 197,250,000   $ 197,250,000 $ 197,250,000 $ 181,050,000
Available borrowing capacity             102,700,000   $ 102,700,000 $ 102,700,000  
Repayments of mortgage loan             $ 22,585,000 $ 36,473,000      
Number of non-recourse mortgages repaid | MortgageLoan             3   3 3  
Number of non-recourse mortgages | MortgageLoan             8   8 8 11
Mortgage loan fair value             $ 53,000,000   $ 53,000,000 $ 53,000,000 $ 76,300,000
Balance of Non Recourse Mortgages             53,157,000 [1]   53,157,000 [1] 53,157,000 [1] $ 75,700,000
Interest Rate Cap                      
Debt Instrument [Line Items]                      
Number of interest rate cap agreements | Derivative         1 1          
Notional amount         $ 30,000,000 $ 30,000,000          
Premium paid         $ 55,000 $ 115,000          
Expiration date of interest rate cap         Mar. 31, 2019 Mar. 31, 2019          
Derivative interest rate cap, payment received or accrued from counterparties                 39,000 39,000  
Three Mortgages Utilizing Borrowings under Credit Agreement                      
Debt Instrument [Line Items]                      
Repayments of mortgage loan             21,700,000        
Sparks Medical Building/Vista Medical Terrace Floating Rate Mortgage Loan                      
Debt Instrument [Line Items]                      
Repayments of mortgage loan       $ 4,100,000              
Centennial Hills Medical Office Building floating rate mortgage loan                      
Debt Instrument [Line Items]                      
Repayments of mortgage loan   $ 9,700,000                  
Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan                      
Debt Instrument [Line Items]                      
Repayments of mortgage loan $ 7,900,000                    
LIBOR | Interest Rate Cap                      
Debt Instrument [Line Items]                      
Derivative instruments, LIBOR rate         1.50% 1.50%          
Credit Agreement                      
Debt Instrument [Line Items]                      
Outstanding borrowing     $ 300,000,000       $ 300,000,000   $ 300,000,000 $ 300,000,000  
Increase in borrowing capacity     $ 50,000,000                
Unsecured revolving amended credit agreement terminated date     2022-03                
Number of additional six month extension options | Option     2                
Proceeds from Lines of Credit     $ 50,000,000                
Credit facility, Interest Rate Terms             one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%.        
Base rate description             the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.        
Facility fee payable on commitment             0.20%        
Credit Agreement | LIBOR                      
Debt Instrument [Line Items]                      
Margin points added to the reference rate             1.15%        
Credit Agreement | Base Rate                      
Debt Instrument [Line Items]                      
Margin points added to the reference rate             0.15%        
Credit Agreement | Swingline/Short-Term Loans                      
Debt Instrument [Line Items]                      
Outstanding borrowing     30,000,000                
Credit Agreement | Letters of Credit                      
Debt Instrument [Line Items]                      
Outstanding borrowing     $ 40,000,000                
Credit Agreement | Minimum                      
Debt Instrument [Line Items]                      
Facility fee payable on commitment     0.15%                
Credit Agreement | Minimum | LIBOR                      
Debt Instrument [Line Items]                      
Margin points added to the reference rate     1.10%                
Margin points added to the base rate     1.00%                
Credit Agreement | Minimum | Base Rate                      
Debt Instrument [Line Items]                      
Margin points added to the reference rate     0.10%                
Credit Agreement | Minimum | Federal Funds Effective Rate                      
Debt Instrument [Line Items]                      
Margin points added to the base rate     0.50%                
Credit Agreement | Maximum                      
Debt Instrument [Line Items]                      
Facility fee payable on commitment     0.35%                
Credit Agreement | Maximum | LIBOR                      
Debt Instrument [Line Items]                      
Margin points added to the reference rate     1.35%                
Credit Agreement | Maximum | Base Rate                      
Debt Instrument [Line Items]                      
Margin points added to the reference rate     0.35%                
[1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail)
$ in Thousands
6 Months Ended
Jun. 30, 2018
USD ($)
Debt Instrument [Line Items]  
Covenant, Tangible net worth $ 125,000
Tangible net worth $ 188,737
Total leverage 39.90%
Secured leverage 8.10%
Unencumbered leverage 36.20%
Fixed charge coverage 4.10%
Maximum  
Debt Instrument [Line Items]  
Covenant, Total leverage 60.00%
Covenant, Secured leverage 30.00%
Covenant, Unencumbered leverage 60.00%
Minimum  
Debt Instrument [Line Items]  
Covenant, Fixed charge coverage 1.50%
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Outstanding Balance $ 53,157 [1] $ 75,700
Less net financing fees [1] (625)  
Plus net debt premium [1] 274  
Total mortgages notes payable, non-recourse to us, net 52,806 [1] $ 75,359
Vibra Hospital-Corpus Christi fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 2,573  
Debt Instrument Interest Rate Stated Percentage 6.50%  
Maturity Date 2019-07  
700 Shadow Lane and Goldring MOBs fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 5,961  
Debt Instrument Interest Rate Stated Percentage 4.54%  
Maturity Date 2022-06  
BRB Medical Office Building fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 6,028  
Debt Instrument Interest Rate Stated Percentage 4.27%  
Maturity Date 2022-12  
Desert Valley Medical Center Floating Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 4,877  
Debt Instrument Interest Rate Stated Percentage 3.62%  
Maturity Date 2023-01  
2704 North Tenaya Way fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 6,940  
Debt Instrument Interest Rate Stated Percentage 4.95%  
Maturity Date 2023-11  
Summerlin Hospital Medical Office Building III fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 13,198  
Debt Instrument Interest Rate Stated Percentage 4.03%  
Maturity Date 2024-04  
Tuscan Professional Building fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 4,273  
Debt Instrument Interest Rate Stated Percentage 5.56%  
Maturity Date 2025-06  
Phoenix Children's East Valley Care Center Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 9,307  
Debt Instrument Interest Rate Stated Percentage 3.95%  
Maturity Date 2030-01  
[1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting - Additional Information (Detail)
6 Months Ended
Jun. 30, 2018
Segment
Segment Reporting [Abstract]  
Number of reportable segments 1
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Impact of Hurricane Harvey - Additional Information (Detail)
3 Months Ended 4 Months Ended 6 Months Ended 10 Months Ended
Jun. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Aug. 31, 2017
Building
Unusual Or Infrequent Item [Line Items]          
Hurricane related insurance recoveries $ 194,000   $ 1,162,000    
Hurricane insurance recoveries in excess of property damage write-downs     4,535,000    
Hurricane Harvey, Extensive Water Damage | Houston, Texas          
Unusual Or Infrequent Item [Line Items]          
Number of medical office buildings | Building         5
Hurricane Harvey          
Unusual Or Infrequent Item [Line Items]          
Additional insurance recovery proceeds     5,500,000    
Hurricane related insurance recoveries     12,500,000    
Hurricane Harvey | Business Interruption          
Unusual Or Infrequent Item [Line Items]          
Hurricane related insurance recoveries $ 194,000     $ 1,200,000  
Hurricane insurance recoveries in excess of property damage write-downs     $ 4,500,000    
Hurricane Harvey | 2017 business interruption          
Unusual Or Infrequent Item [Line Items]          
Hurricane related insurance recoveries   $ 500,000      
Properties Damaged and Temporarily Closed from Hurricane Harvey | Spring, Texas | Cypresswood Professional Center          
Unusual Or Infrequent Item [Line Items]          
Number of medical office buildings | Building         2
Properties Damaged and Temporarily Closed from Hurricane Harvey | Kingwood, Texas | Professional Buildings at Kings Crossing          
Unusual Or Infrequent Item [Line Items]          
Number of medical office buildings | Building         2
Properties Damaged and Temporarily Closed from Hurricane Harvey | Kingwood, Texas | Kelsey-Seybold Clinic at Kings Crossing          
Unusual Or Infrequent Item [Line Items]          
Number of medical office buildings | Building         1
EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

  • #%! 4HW(4I7(4IW(4J7(4JW(4K7(4KW(4L7(4LPH4LPH4LPH4 MLPH4LPH4LPH4LPH4LPH4LPH4LPH4LTH4LTH4LTH4LTH4LTH4LTH4LTH4LTH4 MLTH4LTH4LPY1S#J\HEG;-JV4KO\B^31F>:C/VO\UTV]02P$"% ,4 " #6 M@@A-'R// \ 3 @ "P @ $ 7W)E;',O+G)E;'-0 M2P$"% ,4 " #6@@A-9O,+8(( "Q $ @ 'I M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( -:""$V- ESI[@ "L" 1 M " 9D! !D;V-0&UL4$L! A0#% @ UH((37MR12!D @ % @ !@ M ( !]P@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ UH((3;1"6"Q:! 010 !@ ( !71, 'AL+W=O MT7 !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ UH((3&PO=V]R:W-H965T&UL4$L! A0#% @ UH((36X>=*BS 0 T@, !D M ( !1"4 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ UH((38#W7=&S 0 T@, !D ( !!2L 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ UH(( M36/.R/:W 0 T@, !D ( !QC 'AL+W=O&PO=V]R:W-H965TW@$ $% 9 " 9TT !X;"]W;W)K M&UL4$L! A0#% @ UH((31UITXFW 0 T@, M !D ( !LC8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ UH((3120V%'&PO=V]R:W-H965T M""$U$?X#C90( *@( 9 M " ?1$ !X;"]W;W)K&UL4$L! A0# M% @ UX((3:0L)&59 @ #P@ !D ( !D$< 'AL+W=O M&PO=V]R:W-H965T""$VI4S!7/@( ,,' 9 " 8%- M !X;"]W;W)K&UL4$L! A0#% @ UX((379] MI47 @ ; L !D ( !]D\ 'AL+W=O&PO=V]R:W-H965T""$T_!:,\XP( +8* 9 " 2I5 !X;"]W;W)K&UL4$L! A0#% @ UX((30Z?#(* VWP" #," &0 @ %@6@ >&PO M=V]R:W-H965T""$T)=&UL4$L! A0#% @ UX((32+H&/K7 0 :P4 !D ( ! M&& 'AL+W=O&PO=V]R:W-H965T""$T1W\ZK9 ( !T( 9 M " 4]D !X;"]W;W)K&UL4$L! A0#% M @ UX((3;A$JB\;!@ 9B4 !D ( !ZF8 'AL+W=O&PO=V]R:W-H965T" M"$V-YDY^:4$ -D; 0 4 " 6AY !X;"]S:&%R9613=')I M;F=S+GAM;%!+ 0(4 Q0 ( ->""$VAM1\Q5@( %L, - M " 0.[ !X;"]S='EL97,N>&UL4$L! A0#% @ UX((3=IC/#.1 P M31L \ ( !A+T 'AL+W=O""$U,$DM:J@$ ' 9 : " 4+! !X;"]?""$WAC\E6JP$ +<9 M 3 " 23# !;0V]N=&5N=%]4>7!E&UL4$L%!@ 0 R #( D T #% $! end XML 54 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 160 225 1 true 68 0 false 13 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.uhrit.com/20180630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Statements of Income Sheet http://www.uhrit.com/20180630/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.uhrit.com/20180630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.uhrit.com/20180630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.uhrit.com/20180630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statement of Cash Flows Sheet http://www.uhrit.com/20180630/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows Condensed Consolidated Statement of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - General Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureGeneral General Notes 7 false false R8.htm 100070 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Notes 8 false false R9.htm 100080 - Disclosure - Dividends Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureDividends Dividends Notes 9 false false R10.htm 100090 - Disclosure - Acquisitions and Dispositions Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureAcquisitionsAndDispositions Acquisitions and Dispositions Notes 10 false false R11.htm 100100 - Disclosure - Summarized Financial Information of Equity Affiliates Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates Summarized Financial Information of Equity Affiliates Notes 11 false false R12.htm 100110 - Disclosure - Recent Accounting Pronouncements Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 12 false false R13.htm 100120 - Disclosure - Debt and Financial Instruments Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureDebtAndFinancialInstruments Debt and Financial Instruments Notes 13 false false R14.htm 100130 - Disclosure - Segment Reporting Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureSegmentReporting Segment Reporting Notes 14 false false R15.htm 100140 - Disclosure - Impact of Hurricane Harvey Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureImpactOfHurricaneHarvey Impact of Hurricane Harvey Notes 15 false false R16.htm 100150 - Disclosure - Recent Accounting Pronouncements (Policies) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureRecentAccountingPronouncementsPolicies Recent Accounting Pronouncements (Policies) Policies http://www.uhrit.com/20180630/taxonomy/role/DisclosureRecentAccountingPronouncements 16 false false R17.htm 100160 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Tables http://www.uhrit.com/20180630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions 17 false false R18.htm 100170 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables Summarized Financial Information of Equity Affiliates (Tables) Tables http://www.uhrit.com/20180630/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates 18 false false R19.htm 100180 - Disclosure - Recent Accounting Pronouncements (Tables) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureRecentAccountingPronouncementsTables Recent Accounting Pronouncements (Tables) Tables http://www.uhrit.com/20180630/taxonomy/role/DisclosureRecentAccountingPronouncements 19 false false R20.htm 100190 - Disclosure - Debt and Financial Instruments (Tables) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables Debt and Financial Instruments (Tables) Tables http://www.uhrit.com/20180630/taxonomy/role/DisclosureDebtAndFinancialInstruments 20 false false R21.htm 100200 - Disclosure - General - Additional Information (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureGeneralAdditionalInformationDetail General - Additional Information (Detail) Details 21 false false R22.htm 100210 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Details http://www.uhrit.com/20180630/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables 22 false false R23.htm 100220 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Details 23 false false R24.htm 100230 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Details 24 false false R25.htm 100240 - Disclosure - Dividends - Additional Information (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureDividendsAdditionalInformationDetail Dividends - Additional Information (Detail) Details 25 false false R26.htm 100250 - Disclosure - Acquisitions and Dispositions - Additional Information (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureAcquisitionsAndDispositionsAdditionalInformationDetail Acquisitions and Dispositions - Additional Information (Detail) Details 26 false false R27.htm 100260 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Details 27 false false R28.htm 100270 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail Limited Liability Companies Accounted for Under Equity Method (Detail) Details 28 false false R29.htm 100280 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Details 29 false false R30.htm 100290 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLimitedLiabilitiesAccountedForUnderEquityMethodDetail Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) Details 30 false false R31.htm 100300 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLimitedLiabilitiesAccountedForUnderEquityMethodParentheticalDetail Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) Details 31 false false R32.htm 100310 - Disclosure - Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsOfLimitedLiabilitiesAccountedForUnderEquityMethodDetail Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) Details 32 false false R33.htm 100320 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) Notes http://www.uhrit.com/20180630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcsAccountedUnderEquityMethodDetail Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) Details 33 false false R34.htm 100330 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Parenthetical) (Detail) Notes http://www.uhrit.com/20180630/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcsAccountedUnderEquityMethodParentheticalDetail Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Parenthetical) (Detail) Details 34 false false R35.htm 100340 - Disclosure - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) Details 35 false false R36.htm 100350 - Disclosure - Recent Accounting Pronouncements - Additional Information (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetail Recent Accounting Pronouncements - Additional Information (Detail) Details 36 false false R37.htm 100360 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail Debt and Financial Instruments - Additional Information (Detail) Details 37 false false R38.htm 100370 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Details 38 false false R39.htm 100380 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Details 39 false false R40.htm 100390 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail Segment Reporting - Additional Information (Detail) Details 40 false false R41.htm 100400 - Disclosure - Impact of Hurricane Harvey - Additional Information (Detail) Sheet http://www.uhrit.com/20180630/taxonomy/role/DisclosureImpactOfHurricaneHarveyAdditionalInformationDetail Impact of Hurricane Harvey - Additional Information (Detail) Details 41 false false All Reports Book All Reports uht-20180630.xml uht-20180630.xsd uht-20180630_cal.xml uht-20180630_def.xml uht-20180630_lab.xml uht-20180630_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 59 0001564590-18-020497-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-18-020497-xbrl.zip M4$L#!!0 ( ->""$W1AI: L,< >�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ò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� 0 M " 0 !U:'0M,C Q.# V,S N>&UL4$L! A0#% @ MUX((36:(/PC.%0 #>P ! ( !WL< '5H="TR,#$X,#8S M,"YX